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1 ABBREVIATIONS AND THEIR CLARIFICATIONS 
 
APOPTIN SMALL PROLINE-RICH PROTEIN 
BAX  BCL2-ASSOCIATED X PROTEIN 
BD BASIC DOMAIN 
BH3 BCL-2-HOMOLOGY DOMAIN 3  
C-ABL TYROSINE KINASE 
CD95 DEATH-RECEPTOR PROTEIN 
CHK1/2 CHECK POINT KINASE 
CTD C-TERMINAL DOMAIN 
E1A ADENOVIRAL ONCOGENE 
E2F1 TRANSCRIPTION FACTOR 
GRAMD4 DEATH-INDUCING PROTEIN 
HPV HUMAN PAPILLOMAVIRUS 
HDM2 HUMAN HOMOLOGUE OF MDM2 
HELA CERVICAL CANCER CELL LINE 
HIC1 HYPERMETHYLATED IN CANCER 1 PROTEIN 
H1299 NON-SMALL CELL LUNG CARCINOMA  
IASPP ONCOPROTEIN (ASPP-INHIBITING) 
ID INHIBITORY DOMAIN 
JNK C-JUN N-TERMINAL KINASE 
K562 ERYTHROLEUKEMIC CELL LINE 
LSD1 LYSINE-SPECIFIC DEMETHYLASE 
MDM2 MURINE DOUBLE MINUTE 2 PROTEIN 
MCF-7 BREAST CANCER CELL LINE 
MCM7 DNA REPLICATION LICENSING FACTOR 
MIRNA MICRORNA 
NEDD4 NEURONAL PRECURSOR CELL-EXPRESSED DEVELOPMENTALLY 
DOWNREGULATED 4 
NETRIN GUIDANCE FACTOR 
N4BP1 NEDD4-BINDING PARTNER-1 
PIAS PROTEIN INHIBITOR OF ACTIVATED STAT 
PIN-1 ISOMERASE 
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PPIG3/DNA POLYPROPYLENIME DENDRIMER 
PRB RETINOPLASMA PROTEIN 
PUMA P53 UP-REGULATED MODULATOR OF APOPTOSIS  
P300/CBP CO-ACTIVATING PROTEINS 
RUNX RUNT-RELATED TRANSCRIPTION FACTOR 
SAM STERILE ALFA MOTIF 
SET9 HISTONE METHYLTRANSFERASE 
SHRNA SMALL-HAIRPIN RNA 
SIRNA SMALL-INTERFERING RNA 
SUMO SMALL UBIQUITIN-RELATED MODIFIER 
TA TRANSACTIVATING 
YAP1 YES-ASSOCIATED PROTEIN 1 
37AA SMALL HYBRID PEPTIDE 
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2 P73 
 
2.1  Main information of p73 
2.1.1 Family, structure, cellular location, levels in cancer cells, isoforms 
In 1997, Kaghad et al. found a novel monoallelically expressed tumor suppressor gene related 
to p53 at region 1p36 in several tumor cell lines and named it p73 (Kaghad et al. 1997). p73 
shares a significant sequence similarity with the DNA-binding (63% similarity), 
transactivation (29% similarity) and oligomerization (38% similarity) domains of p53. The 
homology of p73 with p53 led to assumptions that p73 could play as important a role in cell 
cycle regulation and growth control as p53. After few additional studies, it became clear that 
overexpressed p73 activated the transcription of p53-responsive genes and inhibited cell 
growth by inducing apoptosis (programmed cell death) and cell cycle arrest (Jost, Marin & 
Kaelin 1997). Now, 14 years later the results from p73 research have indeed proven that p73 
possess an important role as a tumor suppressor and may also be one way towards more 
efficient cancer therapy. 
 
The p53 family consists of transcription factors p53, p63 and p73, which are highly 
homologous in the previously mentioned domains but differ in their C-terminus (Chi, Ayed & 
Arrowsmith 1999). p73 and p63 have more similarity in their domain structures when 
compared with p53. It has been estimated that this tumor suppressor family was generated 
from a p73/p63-like ancestral gene. The C-terminal domains (CTDs) are the variable parts, 
possessing tendency towards alternative splicing and post-translational modifications (Sauer 
et al. 2008). The CTDs affect DNA binding and transcriptional activity of the transcription 
factor; the different DNA-binding characteristics seem to determine the predominant role of 
the family members in cellular stress response or in developmental processes. The C-
terminus of p53 which has a basic domain (BD) but p63 and p73 have a sterile α motif 
(SAM) domain and an inhibitory domain (ID) (Chi, Ayed & Arrowsmith 1999). The SAM 
domain is involved in protein-protein interactions. The structures of p53-family members are 
presented in Figure 1. 
 
Human p73 transcripts lead to several C-terminal splice variants, from p73α to p73η (De 
Laurenzi et al. 1998). The p73 gene contains P1 promoter, which produces transactivating TA 
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isoforms (Killick et al. 2011). An alternative promoter P2 in intron 3 leads to transcription of 
dominant negative ΔN isoforms, which are able to inhibit the transactivation of the TA-
forms. 
 
Figure 1. The structures of p53-family members. The basic core is based on a central sequence-
specific DNA binding domain (DBD), an N-terminal transactivation domain (TA) and a C-terminal 
oligomerization domain (OD). p73 and p63 have a SAM-domain. ΔN-forms lack the transactivation 
domain and show opposing functions compared with TA-forms (Stiewe 2007). 
 
 
The expression levels of p53-family members are usually upregulated in cancer (Ng et al. 
2000); (Choi et al. 2002); (Hong et al. 2007); (Uramoto et al. 2004). Studies have connected 
upregulation of p73 to the formation of distant metastasis and vascular invasion but the main 
connection may only be with the dominant-negative isoform of p73 (ΔNp73). This topic will 
be discussed more detailed later in Chapter 2. 
2.1.2 The functions of p73 and response to DNA damage  
The p53-family members are connected to several functions in cell cycle regulation, 
development and tumorigenesis. The family members have similar but also individual roles 
(Levrero et al. 2000). p53 mainly acts as a tumor suppressor in stress situations and p63 is 
vital for ectoderm (the embryo layer, where the skin, nervous system and sense organs 
originate) development. p73 seems to take part in regulating both, the stress responses and 
developmental processes (e.g. differentiation of neural stem cells) (Agostini et al. 2010). 
Deficiency of p73 has shown to cause severe neurological and immunological defects in 
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mice, expecially the lack of dominant-negative isoform ΔNp73, which induces symptoms of 
neurodegeneration (Wilhelm et al. 2010).  
 
Cells deficient in p73 and p63 are unable to repair DNA damages, e.g. broken DNA double 
strand (Lin 2009); (Puig et al. 2003). This leads to enhanced tumor formation and 
progression. p73 has been shown to act also as a T-cell specific tumor suppressor in a mouse 
model, indicating that the loss of p73 results in an increased incidence of thymic lymphomas 
when compared to the loss of p53 alone (Nemajerova 2009). This finding reveals a possible 
role for p73 in the formation of human leukemias and lymphomas.  
2.1.3 Apoptosis and cell cycle arrest via p73 
2.1.3.1 Apoptosis 
Several factors are connected to p73 mediated cell death and the network is complex. The 
cancer cells undergo DNA damage eg. in response to treatment with DNA damaging agents 
(e.g. anticancer drugs) or irradiation. This then induces increased levels of the p53 family 
members. The severity of DNA damage on the cell defines the ultimate result (Bitomsky 
2009). When the cell is exposed to a milder DNA damage, it tries to repair itself or goes to a 
cell cycle arrest. Apoptosis is what happens if the cell is confronted with DNA damage 
impossible to be repaired.  
 
The observation that most of p73 is localized in the cell’s nucleus and is retained there during 
apoptosis, has led to suggestions that p73 may not have direct effect on the pro-apoptotic 
factors located outside the nucleus (Melino et al. 2004). It has been proposed an apoptotic 
pathway controlled p73 would involve p73’s direct PUMA (p53 up-regulated modulator of 
apoptosis) transactivation, which then is capable of directly changing the conformation and 
mitochondrial relocalization of Bax (Bcl2-associated X protein). This finding proposes a p73 
induced PUMA and Bax mediated mitochondrial pathway leading to cell death. The 
dominant-negative isoforms of p73 have a repressing effect on p73-induced apoptosis. They 
control the PUMA and Bax pathway negatively and therefore inhibit TAp73- and p53-
induced apoptosis.  
 
The JNK (c-Jun N-terminal kinase) is an important mediator of the stress response in DNA 
damaged cells (Jones, Dickman & Whitmarsh 2007). There has been found a link between 
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p73 and JNK during exposure to chemotherapeutic agents (e.g. cisplatin). Studies by Jones et 
al. show, that JNK creates a complex with p73 and phosphorylates p73 at numerous amino 
acid residues (e.g. serine, threonine), leading to stabilization of p73, enhanced p73-
transcriptional activity, and apoptosis. More specifically, JNK causes stabilization and 
apoptotic effects through TAp73 isoform while at the same time promoting the degradation 
of antiapoptotic ΔNp73 isoform (Dulloo et al. 2010). The tyrosine kinase c-Abl has also been 
shown to phosphorylate p73 when cells are exposed to DNA damage i.e. caused by gamma-
irradiation or DNA damaging agent (e.g. cisplatin) in vitro and in vivo (Agami et al. 1999). 
These two kinases, JNK and c-Abl regulate p73 apoptotic response during DNA damage and 
therefore are important modulators of a cytotoxic response. 
2.1.3.2 Cell cycle arrest 
p73 induces cells to apoptoses and also causes cell cycle arrest. First studies, carried out in 
1998 by Zhu et al. in H1299 (non-small cell lung carcinoma) cells showed that p73-
dependent cell cycle arrest occurs in both the G as well as G2-M phase similar to that induced 
by p53 (Zhu et al. 1998) (Cell cycle phases are shown in Figure 2). 
 
Only few studies have analysed the regulation of p53-family proteins during cell cycle 
progression. The amount of these proteins is different depending on the cell cycle phase 
(Lefkimmiatis et al. 2009). When MCF-7 (breast cancer) cells were examined, the 
concentration of TAp73α isoform was higher in S phase cells, whereas ΔNp73α was at 
highest level in G1-S phase transition and in the beginning of S phase. This suggests that the 
upregulated levels of p73 seen in cancers may support abnormal cellular proliferation (via 
growth progression genes involved in the cell cycle phases) and play a part in cancer 
initiation or growth. 
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Figure 2. Cell cycle with different phases. p73-mediated cell cycle arrest takes place during G1 phase 
and from G2 to M phase. G1 phase is a growth stage, allowing cell to produce RNAs, proteins and 
other cellular molecules. In G2 phase cell duplicates chromosomal proteins and DNA. In M phase the 
cell goes through mitosis at four stages; prophase, metaphase, anaphase and telophase (St. Rosemary 
Educational School 2010). 
 
2.2  p73 mutations in cancer cells and the effect of p53 mutations to p73 function 
Usually the loss of heterozygosity in tumors is found in the 1p chromosome region, where 
also various tumor suppressor genes are located (Han et al. 1999). Unlike p53, which is 
mutated almost in half of the human cancers, p73 appears to be mutated in human cancers 
when various types of tumors have been investigated, including breast, colorectal, gastric, 
lung, pancreatic cancer and neuroblastomas (Hollstein et al. 1994); (Yoshikawa et al. 1999); 
(Takahashi et al. 1998); (Mai et al. 1998); (Nomoto et al. 1998). When originally discovered 
no mutations of p73 were found in 15 cancer cell lines (Kaghad et al. 1997). p53 mutations 
and p73 mutations together in same cell line have only been found in 2 out of 17 lung cancer 
cell lines. (Yoshikawa et al. 1999).  
 
Even though the overall amount of mutations is small, a few have been identified. A mutation 
of p73α (G264W) was shown to have a suppressing effect on the transactivating wild-type 
p73α, when three naturally occurring p73 mutants were examined from lung cancer cell lines 
(Huqun et al. 2003). The p73 mutation P425L was seen to reduce the ability to activate p73 
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and p53 regulators (e.g. Bax, MDM2) (Naka et al. 2001). The biological significance of these 
p73 mutations clearly needs more studies. The fact that mutations in both p53 and p73 genes 
rarely occur simultaneously emphasises the family members’s individual roles in cancers and 
the narrow mutation profile of p73 is very positive when considering for anticancer therapy. 
 
In cells that have mutated p53 the function of tumor suppressor p53-family members is 
particularly important. In the presence of mutant p53, at least p73 has been shown to preserve 
the cell growth suppression through induction apoptosis and cell cycle arrest, a p21-mediated 
downstream pathway has also been proposed (Willis et al. 2003). However, mutant p53 
proteins are also capable of binding and down regulating several p73 and p63 isoforms (both 
TA- and ΔN-forms, from α to Δ) resulting to inhibition of p73 and p63 functions (Gaiddon et 
al. 2001). The inhibition level depends on the binding efficiency. Specific DNA binding and 
the oligomerization domains in p73 are required for the interaction of p73 with mutant p53. 
In the case of mutant p53, only the core domain is needed for the interaction (Strano et al. 
2000). 
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3 P73 AND ITS REGULATION, INTERACTIONS AND ROLE IN 
CHEMOSENSITIVITY  
 
3.1 p73 regulators 
The network surrounding p73 is extensive, consisting of at least 53 proteins and 176 
interactions with different functions from p73 upregulation to its transcriptional activation 
(Tozluoǧlu et al. 2008). The categories are shown in Table 1. This chapter will clarify the 
factors controlling the function of p73. 
 
Table 1. Proteins connected with p73 grouped into functional categories, consisting of upregulation, 
activation, suppression, degradation and transcriptional activation. One protein may be in many 
categories, if it shows different functions. p73 isoform ΔN and factor pRB are put separately, because 
their role is uncertain in several paths (Tozluoǧlu et al. 2008)  
Functional categories 
Upregulation Activation Suppression Degradation 
Transcriptional 
activation 
E2F1 Pin-1 RACK1 Cyclin G hTERT 
Chk2 c-Jun MDM2 Ubc-9 Apaf-1 
TGFβ ASPP1/2 MDMX Cullin PUMA 
ZEB p38 CTF2 Itch Bax 
Tax PML WT1 NQO1 Scotin 
E1A MM1 SIRT1 UFD2a p21 
  c-Abl E4orf6 Roc1 GADD45 
  YAP Akt   14-3-3σ 
  p300/CBP PIAS-1   IGF-BP3 
  Chk1 Daxx   GADD 153/CHOP 
 
p19
ras
 
Amphiphysin 
IIb-1   Noxa 
pRB PKCδCF Wwox   Killer/DR5 
p73 ATM Cyclin   PIG3 
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A/B:CDK1/2 
ΔNp73 ATR PKA-Cβ   CD95 
  PMS2 Pirh2   p53AIP1 
  NEDL2     p53R2 
  HIPK2       
  PML-NB       
 
3.2 Upregulation by E2F1, EA1, Chk1/Chk2  
E2F1 is a nuclear transcription factor which has an oncogenic as well as pro-apoptotic 
properties. It is involved in the control of the cell-cycle, specifically the transition from G1 
phase to S phase (Tozluoǧlu et al. 2008). Phosphorylation of E2F1 is the key mechanism 
causing its activation. E2F1 acts as a direct transcriptional regulator for p73 and intracellular 
levels of E2F1 and p73 are important factors determining cell fate (Ozaki 2009). The 
transcriptional activity of p73α is due to E2F1’s amino acid residues 1-117. Amino acid 
residues 118 to 285 of E2F1 have an essential role in the regulation of p73α expression 
levels. 
 
E2F1 controls p73 in the presence and absence of DNA damage (Urist et al. 2004). The E2F1 
induced expression of p73 leads to activation of p53-responsive target genes and to cell cycle 
arrest or apoptosis (Stiewe, Putzer 2000); (Tozluoǧlu et al. 2008). Deregulated expression of 
E2F1 leads to proteolytic degradation of p73 in a proteasome-independent manner: The 
deregulation of E2F1 is a common genetic alteration in human tumours (Bell, Ryan 2004). 
The activity of E2F1 can be inhibited by it forming a complex with pRB (a retinoplasma 
protein, tumor suppressor) (Tozluoǧlu et al. 2008). 
 
E1A is an adenoviral oncogene that when added to the  cancer cells (studied e.g. in head and 
neck cancer cell lines), it significantly increases the expression of transcriptionally activating 
p73 isoform TAp73 but does not have any effect on the dominant negative suppressive 
isoform ΔNp73 (Flinterman 2005). In the absence of functional p53, E1A and Apoptin (viral 
proteins added to cancer cells) have the ability to activate apoptotic pathways involving p73 
and p53 targets, and induce efficient tumor cell death (Klanrit et al. 2008). 
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The protein kinases checkpoint kinase Chk1 and Chk2 are central in the induction of cell 
cycle arrest, DNA repair and apoptosis (Tozluoǧlu et al. 2008). p53 and p73 have a similar 
pathway and affect Chk1 and Chk2 but by different mechanisms. In p73 control, Chk1 
activates p73 and Chk2 is more evolved in p73 upregulation. These protein kinases control 
p73 levels after DNA damage in several human tumor cell lines (Urist et al. 2004). Ckh1 and 
Chk2 also regulate the stability and activity of E2F1 after genotoxic stress and through this 
pathway they have an effect on TAp73 transcription. 
3.3 Activation by c-Abl, JNK and ASPP1/ASPP2  
Activation of the tyrosine kinase c-Abl results either in cell cycle arrest in phase G1 or in 
apoptotic cell death (Agami et al. 1999). When DNA damage is recognized c-Abl is activated 
by phosphorylation. After phosphorylation it binds to PXXP- motif of p73 and further 
phosphorylates p73 at the tyrosine and threonine residues. This results in a signaling cascade 
involving e.g. p38 and Pin-1 isomerase, (Tozluoǧlu et al. 2008), which leads to the induction 
of p73-mediated apoptosis (Yuan et al. 1999).   
 
JNK (c-Jun N-terminal kinase) acts mainly as a positive regulator of p73 by inhibiting p73 
degradation and stimulating p73 transcriptional activity (Tozluoǧlu et al. 2008). Paradoxally, 
JNK also binds to MDM2 and induces its transcription, which suppresses p73 activity. The 
role of JNK in p73-network seems to be complex, because it has been seen to promote 
ΔNp73 degradation through a ubiquitin-independent but proteasome-dependent mechanism, 
activated in situations involving genotoxic stress (Dulloo et al. 2010). The apoptosis during 
treatment with DNA-damaging agents has been shown to involve the complex formation 
between JNK and p73, leading to phosphorylation of p73 at numerous amino acid residues 
(e.g. serine, threonine) (Jones, Dickman & Whitmarsh 2007). This event leads to p73 protein 
stabilization, enhanced p300-mediated acetylation of p73 and increased p73-mediated 
transcriptional activity and apoptosis. 
 
ASPP1 and ASPP2 are proteins that can induce apoptosis by binding to p53 family members 
and selectively induce the expression of endogenous p53 target genes (for example PIG3, 
PUMA)(Bergamaschi et al. 2004). They also stimulate the transactivation function of p73 and 
p63 on the promoters (e.g. Bax, PUMA). 
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3.4 Degradation and suppression by Itch, YAP1, PIAS, MDM2 and iASPP  
Itch is an ubiquitin-protein isopeptide (E3) ligase and it is a key controller of p73 protein 
levels (Rossi et al. 2005). Itch controls the levels of p73 by selectively binding to p73 by PY-
motif and by ubiquitinating it. This leads to a proteosome-dependent degradation of p73. 
During DNA damage Itch levels are downregulated, allowing p73 levels to increase. The role 
of of Itch in p73 degradation is similar to that of MDM2 in p53 pathway (Tozluoǧlu et al. 
2008).  
 
Yes-associated protein 1 (Yap1) has been shown to bind to p73 by the same PY-motif and 
increase p73 transactivation of apoptotic genes (Levy 2007). Under normal conditions, YAP1 
makes a complex with co-activator Runx and the complex binds to Itch promoter and 
supports Itch transcription leading to degradation of p73 (Levy, Reuven & Shaul 2008). But 
in situations involving DNA damage, a tyrosine kinase c-Abl phosphorylates Yap1 and the 
Yap1-Runx complex does not develop and the p73 degradation effect by Itch is not 
supported.  Leading to p73 accumulation this Yes-associated protein 1 has thus an important 
role regulating p73 levels during DNA damage.  
 
PIAS (protein inhibitor of activated STAT) proteins interact and modulate the activities of 
various transcription factors and function as SUMO (small ubiquitin-related modifier) ligases 
by sumoylating targets (Kotaja et al. 2002). Sumoylation is a similar process as ubiquitination 
but it does not lead to protein degradation, instead via PIAS proteins it affects target’s 
transcriptional activity on promoters. It has been shown that a RING finger (functional 
domain) of PIAS-1 protein binds to p73 and sumoylates it (Munarriz et al. 2004). This 
phenomenon decreases the p73 transcriptional activity on promoters, for example Bax, and is 
an important factor in the cell cycle regulation. The reduced expression of PIAS1 protein has 
been associated for example with colon cancer development (Coppola et al. 2009). 
 
MDM2 is an E3 ubiquitin ligase, which is an important factor in p53 network but also affects 
p73. It is transcriptionally activated by p73 and, in turn, negatively regulates the function of 
p73 (Zeng et al. 1999). The inactivation of p73 by MDM2 does not occur via a degradation 
pathway (Tozluoǧlu et al. 2008), instead MDM2 has the ability to disrupt the interaction of 
p73 with p300/CBP proteins by competitive binding (Zeng et al. 1999). Only recently it has 
been found that MDM2 indirectly induces the degradation of p73 through interaction with 
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Itch ligase (Kubo et al. 2010). Interaction of MDM2-Itch was seen only in HeLa cells but not 
in H1299 cells, indicating that this observation clearly needs more evidence. Also MDM 
family member MDMX binds to p73 and affects its levels (Ongkeko et al. 1999). 
 
There is an inhibitory member of ASPP protein family connected with p53 family members, 
an oncoprotein called iASPP. It functions as a negative regulator of p73, p53 and p63 
(Robinson et al. 2008). iASPP cooperates with p73 regulators, for example with E1A 
(Bergamaschi et al. 2003).  
 
3.5 Transcriptional regulation by PUMA, Bax, Noxa, CD95 and GRAMD4  
p73 transcriptionally activates a number of genes which are involved in cell cycle control and 
apoptosis. Some of the target genes are in common with other p53 family members and this 
chapter will briefly introduce a few of the main target genes which have been connected with 
p73 without going into the similarity of target genes with other p53 family members.  
 
PUMA belongs to the BH3-only Bcl-2 family of apoptotic regulators (Nakano, Vousden 
2001). In normal conditions the level of PUMA is kept low but up-regulated, for example by 
p53, p73 and E2F1, it causes programmed cell death. PUMA controls apoptosis by regulating 
the release of pro-apoptotic factors from cell’s mitochondria. It also causes conformational 
change of Bax (Bcl-2 family member) and activates its mitochondrial translocation (Bcl-2 
family member)(Tozluoǧlu et al. 2008). Cytochrome c release is follows after the 
mitochondrial translocation of Bax, leading to activation of the caspase cascade and 
eventually to apoptosis (Melino et al. 2004); (Tozluoǧlu et al. 2008). It seems that the p73-
mediated induction of PUMA happens through p73β (Sun 2009). p73 induces also the 
expression of apoptotic Noxa gene after genotoxin treatment, also leading to apoptosis 
(Martin et al. 2009). 
 
CD95 is a gene that encodes for a cell’s death receptor (Schuster 2010). It is regulated by p73 
isoforms TAp73β and ΔNp73 and the effect of each isoform leads to an opposite result 
(Muller 2005). TAp73β directly activates the CD95 via the p53-binding site and also induces 
the expression of proapoptotic Bcl-2 family members in mitochondria. Instead, isoform 
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ΔNp73 inhibits the CD95 transactivation and apoptosis and by doing so, inactivates the tumor 
suppressor function of TAp73β and also p53. 
 
An important and a novel pathway of p73-induced apoptosis was introduced by John et al in 
their studies in 2010 (John et al. 2010). They showed that p73-induced apoptosis after the 
DNA-damage caused by chemotherapeutic drug is partly mediated by GRAMD4 protein 
(alias Death-Inducing-Protein) expression and translocation to the mitochondria. GRAMD4 
physically interacts with Bcl-2, promotes Bax mitochondrial relocalization and 
oligomerization, which proceeds to other events leading to apoptotic cell death. 
 
3.6 The interactions between the p53 family members p53, p73 and p63 in cancer 
The p53 family members have compensatory mechanisms with each other, ensuring that 
apoptotic functions are maintained in cells that lack some family member, e.g. in p53-
deficient cells. The ΔN isoforms of family members act by suppressing the functions of TA 
(transactivating) isoforms. A concominant loss of two family members, p73 and p63 has been 
seen to result in failure of apoptosis in fibroblasts, even though the cells had functional p53 
(Flores et al. 2002). The result indicates the crucial role of other family members in p53-
dependent apoptosis. In T-cells the dependence of p63 and p73 for p53-mediated apoptosis 
was not as clear, indicating a cell type specificity for p53-family interactions (Senoo et al. 
2004). 
 
3.6.1 Compensatory roles 
3.6.1.1 p53 and p73 
p53 and p73 have also shown to have an antagonistic activities with each other in acute 
myeloid leukemia cells via protein kinases Chk1 and Chk2 (Chakraborty 2010). In p53-
impaired cancer cells DNA damage causes accumulation of p73 via Chk1-mediated pathway, 
also by downregulation of dominant regulative isoform of p73 (ΔNp73).  By contrast, when 
p53 function is present, Chk2 induces upregulation of p53 which overshadows p73 activity. 
This means that there is a compensating mechanism for apoptosis between p53 family 
members p53 and p73. 
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3.6.1.2 TAp63/ ΔNp63 and p53 
Compensatory mechanisms are also involved between p63 and p53, with respect to cell cycle 
regulation and DNA damage repair in cancer cells (Yao, Chen 2010). In p53-deficient cancer 
cells expecially the transactivating p63 isoform TAp63 expression upregulates under 
genotoxic stress caused by chemotherapeutic drug. The p53-expressing cells have reduced 
TAp63 promoter activity. 
 
3.6.2 Suppressing roles 
3.6.2.1 ΔNp63α and p73 
The p63 isoform ΔNp63α has an important role in suppressing p73-dependent apoptosis, 
especially in cancer cells that overexpress this isoform (Rocco et al. 2006). ΔNp63α inhibits  
p73-dependent transcription by direct promoter binding and also by physical interaction with 
p73. The expression level of ΔNp63α has been proven to be an essential survival factor in 
head and neck squamos cell carcinoma (HNSCC) (Rocco et al. 2006). 
 
3.6.2.2 ΔNp73 and p53/Tap73 
The tumor suppressor action of p53 and TAp73 can be inactivated by ΔNp73 to block their 
apoptotic function (Muller 2005); (Grob et al. 2001). In the case of TAp73 specifically the 
form TAp73β is inhibited by ΔNp73. Both effects originate from the mitochondria and 
inhibition of CD95 gene transactivation has been proven to be one of the mechanisms 
involved. Naturally, the ΔNp73 is upregulated by the TAp73 and p53. This proves that a 
feedback loop that tightly regulates the functions of TAp73 and p53 exists. ΔNp73 may also 
have a role as a prognostic factor in cancer because upregulated ΔNp73 may be a sign of 
reduced survival possility (Dominguez et al. 2006). 
 
3.7 The interacting p53-family contributes to chemosensitivity and – resistance 
Several studies have shown that p73 levels are upregulated in cancer cells in response to 
DNA damage caused by chemotherapeutic agents (Muller et al. 2006). Recently Seitz et al. 
studied the important role of p53 family members in resistance of hepatocellular cancer cells 
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to chemotherapeutic drugs (Seitz et al. 2010). The study revealed that all endogenous p53 
family members (p53, p63 and p73) are upregulated in response to DNA damaging agents 
and by blocking the p53 family function cancer cells become chemoresistant. 
Chemotherapeutic treatment induced the expression of proapoptotic (e.g. Bax) but also 
antiapoptotic (e.g. MDM2) factors in p53-family mediated downstream pathways. This 
indicates that the final result, sensitivity or resistance to chemotherapy depends on the 
delicate balance between previously mentioned factors.  
 
More precisely, p73 isoform TAp73 has been connected to chemosensitivity in hepatocellular 
carcinoma (Muller 2005). It is upregulated in cancer cells after treatment with anticancer 
agents. In contrast, ΔNp73 is causing the resistance to chemotherapy. The cellular response to 
the chemotherapeutic treatment is unquestionably more dependent on the entire activity of 
p53-family, rather than one member alone (Vilgelm et al. 2010b). 
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4 ROLES OF P73 ISOFORMS IN CANCER 
 
4.1  TAp73 and ΔNp73 
4.1.1 Structures  
p73 has several isoforms with differences in function (Koeppel et al. 2011). The main p73 
isoforms are transactivating TA-forms and aminoterminally truncated ΔN-forms. The p73 
gene contains the P1 promoter, which produces TA isoforms (Killick et al. 2011). An 
alternative promoter P2 in intron 3 leads to transcription of the ΔN isoforms which are able to 
inhibit the transactivation of the TA-forms (Grob et al. 2001); (Zaika et al. 2002). TA- and 
ΔN-forms have opposite roles showing pro-and antiapoptotic functions and the balance 
between these isoforms is the determining the cell fate.  
 
The transactivating TA-isoform have different C-terminal splice forms (subtypes) e.g. α and 
β (Koeppel et al. 2011). These subtypes have different DNA-binding capacity and these 
functions are diverse depending on the tumor cell background (Holcakova 2008). The 
aminoterminally truncated ΔN-forms, also called ΔTAp73 isoforms, exist as ΔNp73, 
ΔN’p73, Ex2p73 and Ex2/3p73 (Concin et al. 2004). ΔNp73 is called a dominant-negative 
isoform because it lacks the transactivation domain of full-length TAp73 (Zaika et al. 2002). 
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Picture 3. The structure of p73 gene. a Genomic organisation of p73 and the splicing variants that 
behind the isoforms of p73. The P1 promoter generates the TA isoforms, while the P2 promoter 
produces the ΔN isoforms. b Schematic representation of the domains encoded by the different 
isoforms of p73. On top, there are indicated the aminoacids included in each domain. TA 
transactivation domain, DBD DNA-binding domain, OD oligomerization domain, SAM SAM domain, 
TID transactivation inhibitory domain (Killick et al. 2011). 
 
4.1.2 Location, expression levels and specific regulators  
While TAp73 and ΔNp73 are mainly located in the cell nuclei, some small amounts are also 
found in the cytoplasm (Nekulova et al. 2010). The levels of p73 isoforms are usually higher 
in tumors than in normal tissue (Faridoni-Laurens et al. 2008). The expression levels of the 
NH2- truncated isoforms of p73 are higher in cancer patients (e.g. in neuroblastoma, ovarian, 
lung, colon and breast) than in healthy individuals (Concin et al. 2004); (Dominguez et al. 
2006) ; (Uramoto et al. 2004). However, TAp73 expression levels show differences between 
cancer types. In ovarian cancer approximately 30 per cent of the patients have also higher 
TAp73 levels, but for example in neck and head squamous carcinoma TAp73 is only weakly 
expressed (Faridoni-Laurens et al. 2008).  
 
The balance between the levels of p73 isoforms, i.e. proapoptotic TAp73 and anti-apoptotic 
ΔNp73, is a key determinant of a cell fate. Studies have shown the regulatory differences of 
p73 isoforms, even though the number of studies seems to still be minimal. The expression of 
endogenous TAp73 is induced at least by E2F and by viral proteins E1A and Apoptin 
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(Waltermann 2003); (Flinterman 2005) ; (Klanrit et al. 2008). The induction of TAp73 via 
E1A and Apoptin activates pro-apoptotic target PUMA, independently of p53.  
 
One specific TAp73-mediated mechanism towards apoptosis is through CD95 gene (Muller 
2005). TAp73 transactivates the CD95 gene via the p53-binding site in the first intron and 
induces the expression of proapoptotic Bcl-2 family members (e.g. PUMA), leading to 
apoptosis. The regulation of TAp73 proteins has been linked to protein family of Netrins and 
their receptors (e.g. receptor DCC, deleted in colorectal cancer) (Roperch 2008). Netrins have 
a wide role in axon guidance, cancer cell survival, tumor angiogenesis and metastasis. Netrin-
1 selectively raises TAp73α protein levels by preventing ubiquitination and degradation but 
does not have any effect on ΔNp73α protein or to the transcripts encoding TAp73α or 
ΔNp73α. The results were seen in human cervical cancer cells. 
 
Induction of the levels of ΔNp73 is partly due to deregulation of the E2F1-responsive P1-
promoter. In contrast to the TAp73 induction, E1A does not have an effect on the levels of 
ΔNp73 (Concin et al. 2004) ; (Flinterman 2005). The regulation of ΔNp73 has been 
connected also to a region within the ΔNp73 gene promoter, containing a binding position for 
HIC1 (Hypermethylated In Cancer 1 protein) (Vilgelm et al. 2010a). HIC1 has been shown to 
negatively regulate ΔNp73 transcription in mucosal epithelial cells, taken from gastric and 
esophageal tumors. The negative regulation resulted in reduction of ΔNp73 levels. 
 
 ΔNp73 is capable of acting as an inhibitor of wild-type p53 and TAp73, by inhibiting 
transactivation function and apoptosis mediated by wild-type p53 and TAp73. It also shuts 
off its own expression so that it can finely regulate the whole p73 system (Grob et al. 2001). 
One mechanism which clarifies the inhibitory function of ΔNp73 is that it competes for the 
DNA binding site with p53 and directly associates with TAp73 (Ishimoto et al. 2002). The 
drug resistance in wild-type p53 tumor cells is also caused by ΔNp73 (Zaika et al. 2002).  
4.2 p73 isoforms connected to cancer prognosis and survival  
p73 is associated with tumor subtypes, clinical outcomes and responses to therapy and the 
levels of its isoforms may serve as markers predicting the future outcome for the cancer 
patient e.g. (Weber et al. 2002). It is clear that the ratio of p73 isoforms, TAp73 and ΔNp73 
with their opposite functions determines the final cell fate (Tomasini 2008). The upregulation 
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of ΔTAp73 variants has been linked to advanced pathologic stage, lymph node metastasis and 
vascular invasion in colon and breast cancer (Concin et al. 2004); (Dominguez et al. 2006); 
(Uramoto et al. 2004). In other cancers poor prognosis, metastasis and advanced tumor stage 
have been mainly correlated with higher expression of ΔTAp73 variants (Dominguez et al. 
2006). 
 
In neuroblastome the ΔNp73 expression level correlates with poor outcome, independent of 
age, primary tumor site and stage (Casciano et al. 2002), the lower levels of ΔTAp73 variants 
(ΔNp73 and ΔN´p73) predict better overall survival. Mice generated specifically deficient for 
ΔNp73 has shown a decrease in size of a tumor without having an effect on apoptosis 
(Wilhelm et al. 2010). The loss of ΔNp73 prevents the transformed cells from iniating a new 
tumor. 
 
The combination of p53 mutational status with p73 isoforms expression have clinical 
significance for drug resistance (Concin et al. 2005). Patients having p53 mutation together 
with high levels of ΔTAp73 variants (ΔNp73 and ΔN´p73) were more likely to have  
chemotherapeutic failure (platinum-based therapy) and had worse overall survival. 
Interestingly patients with p53 mutation that efficiently inhibited TAp73 function had also 
significantly shorter overall survival than patients with unknown p53 mutation. The 
expression levels of p73 isoforms also play a role in response to radiation therapy (Liu et al. 
2006). Overexpression of ΔNp73 found in cervical cancer caused resistance to irradiation, 
whereas TAp73α upregulation was seen in radiation-sensitive cancer tissue. The recurrence 
of the disease was much more evident when ΔNp73 was upregulated whereas TAp73α 
predicted better survival. 
 
The expression levels of p73 and its isoforms can correlate with prognosis but significant 
survival differences have also been observed between the p73 expression alone and p73 
coexpressed with p63, at least in bile duct carcinoma (Hong et al. 2007). In tumors that 
expressed both p73 and p63, the median survival was 13 months while with tumors only 
expressing p73 the median survival was 35 months. The mechanism behind p73 and p63 
causing the poorer survival may be linked to interaction of these isoforms. The interaction of 
ΔNp63 and TAp73 can be one factor leading to the suppression of apoptosis and potential 
oncogenic effects (Rocco et al. 2006). In recent reports the balance between the p73 and p63 
isoforms in cancer prognosis have also been studied, indicating an more important role for an 
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altered ratio of p73 and p63 isoforms than for the overexpressed levels of individual isoforms 
(Iacono et al. 2011). 
4.3 How to distinguish between isoforms 
Proper detection of and discrimination between the tumor suppressor family members of p53 
and their different isoforms in human tissues, especially in tumors is becoming more 
important in cancer research and in clinical care (Rosenbluth 2009). Commercial antibodies 
exist to distinguishing p53 family members and e.g. isoforms TAp73 and ΔNp73. The 
methods used include of western blot analysis, immunochemistry and immunofluorescence. 
Rosenbluth et al. generated polyclonal mouse and rabbit antibodies which are highly specific 
for ΔNp73 protein isoforms without p63 cross-reactivity. The group also found p73 antibody 
Ab4 that is highly specific for α and β C-terminal isoforms of p73 (Tap73α/β) without 
confusing it with other family members. The levels and intracellular distribution of p73 
isoforms TAp73 and ΔNp73 can successfully be detected by immunocytochemical staining 
(Nekulova et al. 2010).  
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5 THERAPEUTIC TARGETS IN THE P73 PATHWAY AND THEIR POTENTIAL 
CLINICAL VALUE 
 
5.1  Potential therapeutic targets 
5.1.1 Itch ligase  
The protein ligase Itch belongs to the NEDD4-like family of ubiquitin E3 ligases (Rossi et al. 
2005). It is connected to several functions in animals and humans and to multiple signaling 
pathways and involvement in pathological conditions (Melino et al. 2008). Itch deficiency in 
humans has been shown to cause e.g. multisystem autoimmune disease and developmental 
abnormalities (Lohr et al. 2010). Itch deficient mice (Itchy mice) possess severe immune and 
inflammatory defects (lung and stomach inflammation, hyperplasia (overgrowth) of lymphoid 
and hematopoietic cells) together with persistent scratching of the skin (Perry et al. 1998). 
 
Itch targets transcriptional regulators and, by doing so, affects cell growth, differentiation and 
apoptotic processes (Melino et al. 2008). The ligase selectively binds to the protein’s PY-
motif, this leads to ubiquitination of p73 and p63 but not p53, because p53 does not possess 
the specific PY-motif for binding (Rossi 2006); (Rossi et al. 2005). Instead the ubiquitination 
and degradation of p53 is regulated by its transcriptional target MDM2 (Wang, Wang & 
Jiang 2011). Ubiquitination of the proteins then leads to their rapid proteasome-dependent 
degradation and is an important mechanism for control of the proteins’ steady-state levels. 
Itch affects both p73 isoforms, TAp73 and ΔNp73 (Rossi et al. 2005). C-terminal isoforms of 
p73, α and β are also under its regulation, while δ and γ lack the PY-domain and are not 
influenced by Itch. 
 
Under normal conditions, Itch maintains the levels of p73 in balance in cells. After the DNA 
damage (e.g. cancer treatment or γ-irradiation) the levels of Itch are down regulated, allowing 
the tumor suppressor levels to stabilize. In cancer cells the Itch down-regulation by DNA-
damaging agents (e.g. doxorubicin) has been shown to be time- and dose-dependent. At the 
same time as the Itch levels go down, the levels of p73 isoform TAp73 levels rise, while 
ΔNp73 levels reduce, making the Itch regulation an interesting therapeutic target. 
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In the near future Itch may be used as a therapeutic target in cancer therapy. Down regulating 
the Itch levels could make cancer cells more sensitive to anticancer agents via upregulated 
p73 apoptotic function and improve the efficacy of the therapy (Hansen et al. 2007). 
Especially cells which lack functional p53 are more sensitive to Itch down regulation, 
indicating that Itch depletion could work in cancers which lack p53 or where it is mutated. 
p73 levels have been also shown to decline more slowly after siRNA-mediated reduction in 
Itch levels (Rossi et al. 2005). 
5.1.2  ASPP1, ASPP2 and iASPP proteins  
ASPP1 and ASPP2 belong to ASPP-family of proteins, which have proapoptotic effects  
(Samuels-Lev et al. 2001). ASPP1 is a C-terminal half of ASPP2 and a homologous to a 
protein called 53BP2. ASPP1 and ASPP2 bind to p53 family members in vitro and in vivo 
and stimulate their apoptotic function (Bergamaschi et al. 2004). The stimulating effect 
comes through promoters of proapoptotic genes, e.g. Bax and PUMA (Samuels-Lev et al. 
2001). ASPP proteins don’t have any effect on cell cycle arrest. The expression of ASPP 
proteins is often down regulated in cancer, lower levels found e.g. from colorectal cancer, 
breast cancer and osteosarcoma (Bergamaschi et al. 2004). In breast carcinoma ASPP 
proteins were down regulated in 60 % of the tumors and only in carcinomas expressing wild-
type p53 but not in those with mutant p53. 
 
Inhibitory member of the ASPP family have also been identified, an oncoprotein called 
iASPP (Bergamaschi et al. 2003). iASPP competes with both ASPP proteins of the binding 
with p53-family members and this way inhibits apoptosis (Robinson et al. 2008). iASPP 
cooperates with p73 regulators, for example with E1A (Bergamaschi et al. 2003). It 
potentiates resistance for cytotoxic drugs and for UV-radiation in tumors (Bergamaschi et al. 
2003). In some tumors iASSP has been found to be overexpressed, mainly in tumors 
expressing wild-type p53. Inhibiting the oncogenic function of iASSP could act as a way to 
improve cancer treatment at least for tumors expressing wild-type p53.  
 
In 2007 Bell et al. described a minimal p53-derived peptide (composed of 37 amino acids) 
that induces apoptosis by binding to iASSP protein, regardless of the tumor cell’s p53 status 
(Bell et al. 2007). By binding to iASPP in p53-null cells the peptide prevents the interaction 
between iASPP and p73, leading to activation of the endogenous p73 target genes and finally 
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to p73-mediated cell death. The effect was seen in vitro and in vivo in several tumor cell 
types but not in normal cells. This 37AA peptide offers potential therapeutic tool to induce 
the p73 expression and enhance the tumor suppressing effect. 
 
5.1.3 Transcription factor E2F1  
E2F1 is an important factor in DNA damage-induced apoptosis and its post-translational 
modification and the control of its expression levels may affect p73-mediated pathways to 
enhance cell death. Regulating the E2F1/p73 pathway is one method to improve the apoptotic 
effects in cancer cells (Rodicker et al. 2001); (Helgason, O'Prey & Ryan 2010). In studies of 
Rödicker et al. the upregulation of E2F1 by using intratumoral injection of an adenovirus 
vector (based on the plasmid) expressing E2F1 led to the induction of p73 and to a more 
powerful apoptotic outcome when combined with administration of chemotherapeutic drug 
(Rödicker F et al. 2001). In pancreatic cancer the response to therapy was seen as a reduction 
in tumor volume. Also in melanoma, cancer cells exposed to topoisomerase II drugs with 
adenovirus mediated E2F1 increased apoptosis in vitro and in vivo (Dong et al. 2002). 
 
Methylation and demethylation of E2F1 are posttranslational events, that regulate the 
intracellular protein levels of E2F1 in respect to DNA damage (Xie et al. 2011); (Kontaki, 
Talianidis 2010). Methylation prevents acetylation and phosphorylation of the E2F1 protein, 
processes which are important e.g. for the activation of protapoptotic p73. During DNA 
damage the methylation of E2F1 is strongly reduced and the stabilizing demethylated effects 
take over, leading to apoptotic responses. Lysine-methyltransferases Set9 and LSD1 have 
opposing functions and regulate whether E2F1 goes through degradation or stabilized 
accumulation. The Set9- and LSD1- mediated pathway is demonstrated in Figure 4. Cancer 
therapy combining DNA-damaging agents and drugs which control Set9 and LSD1 could 
result to a more effective cancer cell death. 
 
 
 
25 
 
 
Picture 4. In p53-deficients cells, lysine-methyltransferases Set9 and LSD1 regulate whether E2F1 
goes through its degradation or activation of proapoptotic genes e.g. p73 during DNA damage. Set9 
and LSD1 have opposing functions. Set9 methylates E2F1 which leads to inhibition of E2F1 
accumulation and apoptotic responses. LSD1 removes Set9 and starts activation of apoptotic genes 
(Kontaki, Talianidis 2010). 
 
5.2 p73 isoforms as therapeutic targets  
As discussed previously, the relative ratio of each p73 isoform (TAp73 and ΔNp73) is a 
critical factor in determining the cell’s fate, as they have opposing effects on cell death. A 
mechanism for regulating the levels of these isoforms can enhance the cancer cells to become 
more sensitive to chemotherapeutic treatment and inhibit tumor growth (Sayan 2010) ; 
(Emmrich et al. 2009). Results to date show, that events and factors leading to proteasomal 
degradation of p73 in most cases do not distinguish between the two isoforms. 
 
Savan et al. found a ring finger ubiquitin ligase named as PIR2, which is able to produce an 
isoform-specific outcome (Sayan 2010). During DNA damage, PIR2 relieves the inhibitory 
effect of ΔNp73 on TAp73 by favoring degradation of ΔNp73 and in this way increases the 
ratio of TA/ΔN to a more apoptotic direction. TAp73 itself induces PIR2. PIR2 levels are 
upregulated during DNA damage but the changes in apoptotic response happen only with 
coexpression with TAp73 or ΔNp73. PIR2 seems to be a promising therapeutic target in 
controlling p73 isoform levels and improving chemosensitivity in tumor cells. 
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To target individual isoform and selectively silence these without having any lowering effect 
on the levels of other isoform is challenging. This has been successfully done in vitro with 
several different cell lines and in vivo against melanoma by using modified antisense 
technology (Emmrich et al. 2009). The mRNA’s of p73 NH2- variants (ΔNp73 and ΔN’p73) 
were targeted in the intron-derived exon 3B, which is unique in both variants. Targeting was 
done with locked nucleid acid (LNA) antisense oligonucleotide (ASO) gapmers which the 
group of Emmrich et al. had developed. Magnetic nanobeads (MNBs) were used to optimize 
in vivo administration, as they prevent diffusion of the complex from the injection site. 
Specific therapeutic efficacy was improved by maintaining the ASO concentrated in tumor.  
 
The results were the specific reduction in tumorigenic p73 transcripts and proteins (ΔNp73 
and ΔN’p73) leading to balance towards apoptotic p73 variant (TAp73). The final response 
was decreased tumor cell proliferation and reduced tumor growth. Treatment with ASO’s 
appear to be a new and successful way to target and control the balance of p73 isoforms in 
cancer cells.  
 
 
 
Table 5. In vivo fluorescence imaging of mice treated with ASO gapmers. Data was measured 1, 
8 and 24 hours after intratumoral injection (Emmrich et al. 2009) 
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6  TARGET VALIDATION AND THERAPEUTIC APPROACHES 
 
 
6.1 Target validation 
Studies to evaluate the potential therapeutic targets of p73 are usually in vitro cancer cell-
based assays. However, in vivo studies of p73 and its targets are more less frequent. What is 
seen in cells in vitro should also be seen in tumors in vivo to give a real estimate of the 
possible success of therapeutic approach. When considering the previously mentioned targets 
in vivo, ASPP1 and ASPP2 have been shown to bind to p53 family members in vivo and 
stimulate their apoptotic function (Bergamaschi et al. 2004). The inhibitory member iASPP’s 
function has also been proven in vivo in tumors (Bergamaschi et al. 2003). Instead, the 
therapeutic approach towards iASPP has been tested only in vitro and the in vivo studies of 
upregulating the ASPP proteins could not be found. To estimate a possible successful 
therapeutic target, main issues which have to be considered are target’s specificity, activity, 
risk of resistance and drugability. In coming chapters the in vitro and in vivo results of the 
main approaches towards p73 targets are introduced. 
6.2 Itch knockdown and inhibition  
In 2005, Rossi et al. demonstrated that the ubiquitin-protein ligase Itch regulates p73 stability 
during DNA damage and also in normal conditions (Rossi et al. 2005). Itch selectively binds 
and ubiquitinates p73 and p63 but does not have any effect on p53. During DNA damage Itch 
is downregulated and because of that, p73 is upregulated. Itch inhibition has been seen to 
regulate chemosensitivity of cancer cells in vitro (Hansen et al. 2007).  The expression of Itch 
was knocked down by siRNA and shRNA (short hairpin interfering RNAs) in HeLa (cervical 
cancer) cells which increased basal expression of p73 and increased the number of apoptotic 
cells seen after genotoxic stress (e.g. cisplatin, doxorubicin). The apoptotic pathway was at 
least p73-mediated. p53-null cells seemed to be more sensitive to Itch-depletion than cells 
with functional p53. This finding points out the importance of Itch knockdown specifically in 
cells, that have absent or mutated p53 (almost half of the tumors). The shRNAs used were 
identical between human and mouse Itch. 
 
Itch ligase connected to p73 has been getting attention in research and shows a good amount 
of in vitro studies but in vivo there are not many. One factor related to p73 and Itch also in 
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vivo studies is a protein interactor and Nedd4-binding partner-1 (N4BP1). N4BP1 is a 
substrate of Itch ligase and these two structurally related proteins have a functional 
interaction with each other (Oberst 2007). N4BP1 binds to the second WW domain of Itch 
and interferes Itch from binding to its substrates. N4BP1 and p73α have the same binding site 
to Itch and by binding to Itch N4BP1 prevents the Itch-mediated ubiquitination of p73, seen 
in vitro and also in vivo in ubiquitylation assays. The role of N4BP1 in tumor progression and 
in response of cancer cells to chemotherapy seems evident.  
 
MicroRNAs (miRNAs) are small RNAs that regulate gene expression at a posttranscriptional 
level by affecting negatively to a target mRNA (messenger RNA) (Ambros et al. 2003). They 
inhibit translation of mRNA by inaccurate antisense base-pairing, the mechanism making 
them different from siRNAs. MicroRNAs are the same size as siRNAs but siRNAs are more 
precise and cause RNA-mediated interference. 
 
MicroRNAs have also been targeted Itch to achieve its degradation by microRNA 106b 
(Sampath et al. 2009). The study was done in several cancer cell lines, H1299, HeLa, K562 
and primary leukemia cells. The cells were exposured to deacetylase inhibitors, which was 
seen to result in transcriptional induction of miRNA 106b (Figure 5). The induction of 
previously mentioned miRNA was connected to the downregulation of Itch levels and to 
enhanced p73-mediated apoptosis. The underlying mechanism was shown to be the 
acetylation of histones around the Mcm7-miR106b promoter caused by deacetylase inhibitors. 
This led to enrollment of e.g. E2F1 to the Mcm7-miR106b promoter and together with host 
gene Mcm7 caused transcriptional induction of miR106b. The p73 up-regulation was 
associated e.g. with p73 target PUMA causing mitochondrial dysfunction, leading to cell 
death.  
 
The chemotherapeutics drugs that activate miR106b should be studied more because miRNA 
may be a possible new mechanism to target Itch in cancer cells. The characterization of 
cancers with low miR106b expression could provide answers to weak apoptotic responses. 
The study also revealed a small group of samples that did not show any induction of miRNA 
in response to deacetylase inhibition, suggesting an alternative pathway regulating Itch.  
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Figure 6. A pathway of deacetylase inhibitor-mediated miRNA induction, leading to Itch 
down regulation and upregulation of Tap73 levels. The final result is mitochondrial 
dysfunction and enhanced cell death, results seen in chronic lymphotic leukemia cells 
(Sampath et al. 2009). 
 
6.3 Nutlin-3 
HDM2 (human double minute oncogene) is a negative regulator of p53 and p73 but which 
does not induce degradation of p73 (Balint, Bates & Vousden 1999). HDM2 binds to p73 and 
suppresses its transcriptional activity. Nutlin-3 instead is a small molecule (molecular weight 
581.5 g/mol), which inhibits the interaction between p73 isoform TAp73 and HDM2 in p53-
null or p53-mutant cells  (Lau et al. 2008). The inhibition of binding between p73 and HDM2 
leads to increased p73 transcriptional activity at protein level and to enhanced apoptosis 
mediated by p73 downstream genes e.g. noxa and PUMA. In the study by Lau et al, Nutlin-3 
treatment resulted to in vitro dose-dependent inhibition of growth in neuroblastoma, colon-
carcinoma and osteosarcoma cells.  
 
The optimal dose of Nutlin-3 was 20-30 µM, being able to interrupt the p73-HDM2 complex 
formation and leading to activation of p73 and its targets. Therapeutic use of Nutlin-3 could 
provide a mechanism to increase p73-mediated apoptosis in cancer cells and improve 
responses to chemotherapeutic treatment. In vitro assays have proven Nutlin’s effect in both, 
wild-type p53 and mutant p53 cells (Lau et al. 2008) ; (Ray 2011) ; (Ambrosini et al. 2007). 
In vivo assays with Nutlin-3 in xenograft tumor models had shown potent effects but only the 
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p53 function has been under investigation (Endo et al. 2011). The connection between p53-
family members is clear but the specific role of p73 in cancer treatment with Nutlin-3 has not 
been evaluated. 
 
6.4  Adenovirus- and PPIG3-DNA -mediated transfer of p73  
An adenovirus-mediated transfer of p73 has been used to induce cell cycle arrest and 
apoptosis in human colorectal cancer cell lines in vitro and in vivo in mice (Sasaki et al. 
2001). Overexpressed exogenous p73 and p63 were able to activate also p53 target genes and 
cause cell death. In the study by Sasaki et al. tumor growth in mice injected with adenovirus-
mediated p73 was reduced, compared to controls which had normal levels of p73. By 
comparison the effect seen with adenovirus-mediated transfer of p53 was weaker than with 
p73. When p73 subtypes were compared, p73β was found to be more than p73α. The 
adenoviral vector is considered suitable for gene therapy in clinical use because it has broad 
host range, high transduction efficiency and the production of purified vector can be easily 
scaled up for larger production, even though problems have also been associated expecially 
with its use as systematic injection (off-target effects and innate-immune responses) (Couto, 
High 2010). 
 
Adenovirus expressing p73β has shown promising results also in the treatment of cervical 
cancer in vivo. The adenovirus based p73 gene therapy targeted to cervical cancer inhibited 
the tumor growth of already established tumors in mice (Das 2006). The human xenografts in 
nude mice were used in the study. Tumor growth inhibition was due to the stable expression 
of p73 protein together with the simultaneous induction of p73 target gene p21. The 
importance of E2F1 gene therapy could offer a potential approach expecially in cervical 
cancer, because the HPV oncoprotein E6 inactivates p53 protein by targeting and 
ubiquitinating it. This causes the p53 based gene therapy to be more prone to failure.  
 
Adenovirus-mediated TAp73β gene transfer leading to overexpression has been shown to 
also overcome the chemotherapeutic drug resistance in vitro in human malignant melanoma, 
caused partly by the dominant-negative form of p73 (ΔNp73) (Tuve 2006). TAp73β 
sensitized 5 of 7 melanoma cell lines to treatment with adriamycin and cisplatin. In xenograft 
mouse models, the overexpressed TAp73β, together with a genotoxic drug, inhibited 
melanoma cell growth. In clinical studies, adenovirus-mediated transfer of p53 in 82 patients 
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with hepatocellular carcinoma showed promising results in one-year follow-up study (Guan 
et al. 2011). After 12 months the survival rates in p53 gene therapy treated group were almost 
50% better than in control group. Both groups received TACE (transcatheter hepatic arterial 
chemoembolization) as a basic treatment. Pain and side-effects were also observed less in the 
p53 gene therapy treated group. This result indicates a possible success for p73-based gene 
therapy in future cancer treatment. 
 
A factor in p73 pathway, E2F1 has also been shown to enhance antitumor activity in vivo 
when used in adenovirus-mediated gene transfer (Dong et al. 2002). In melanoma, the tumor 
growth decreased from 87 to 91 per cent (compared with controls) in nude mice when the 
animals were treated with anticancer drugs combined with E2F1-based gene therapy. In 
pancreatic cancer, the E2F1 adenovirus-mediated gene transfer has also shown similar results 
(Rodicker et al. 2001). The effect of E2F1-based gene therapy has been associated with the 
induction of p73, highlighting the potential use of E2F1/p73 pathway in cancer therapy. 
 
PPIG3/DNA (polypropylenimine dendrimer) nanoparticles in gene transfer have shown good 
results in in vitro but also in vivo in mice (Chisholm et al. 2009). Nanoparticles are proven to 
specifically target and accumulate in tumors after systemic injection, without having any 
transferring effect on the surrounding tissues. The nanoparticles are in a form of well-
organized fingerprint-like structure, having DNA molecules inside. The colloidal stability is 
an important quality of nanoparticles, attained in the study of Chisholm et al. Also the 
expression of transgene in tumor had succeeded, testifying the potential use of PPIG3 
nanoparticles in cancer gene therapy and possibly as a tool for upregulating p73. 
6.5 p73 isoforms 
The importance of targeting towards specific isoforms of p73 has in vitro but also in vivo 
evidence, especially to the dominant-negative isoform ΔNp73. Transgenic mice expressing 
ΔNp73 in the liver showed hepatic histological abnormalities, for example increased 
hepatocyte proliferation causing liver cell adenomas in 3-4 months (Tannapfel et al. 2008). 
After 12 to 20 months the 83 per cent of mice had developed hepatic carcinoma. This proves 
the independent and crucial role of ΔNp73 in tumor development, making it a possible target 
for cancer treatment and a marker in cancer diagnosis. It is also proven to cooperate with Ras 
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oncogene, causing in vivo the development of fibrosarcomas in nude mice (Petrenko, Zaika & 
Moll 2003). 
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7 CONCLUSIONS 
 
The p53-family of tumor suppressors have important functions related to cell cycle 
regulation, development and tumorigenesis, especially they are studied for functions 
concerning cell cycle arrest and apoptosis. p53 is found to be mutated in cancer but p73 
mutations are rare (Kaghad et al. 1997). It is important to maintain the tumor suppressor 
function also in cells having mutated p53 and p73 is able to take the role as a main tumor 
suppressor in cells having mutated p53 (Willis et al. 2003). Rare p73 mutations in cancer 
cells make it a more viable target for anticancer therapy. p73 is regulated by several factors, 
making the approaches towards it complex (Tozluoǧlu et al. 2008). 
 
The levels of p53-family members are upregulated during DNA damage caused by e.g. 
anticancer agents or irradiation (Muller et al. 2006). Blocking the function of those tumor 
suppressors leads to chemoresistance (Seitz et al. 2010).  Instead, the approaches to 
upregulate the p53 and p73 levels and make cancer cells more chemosensitive have been 
studied and may become a future therapy for the treatment of cancer. One promising target is 
Itch ligase, the negative-regulator of p73. Itch is connected e.g. to Runx and YAP1 but the 
connection is only recently studied and the consequences of Itch regulation to those factors 
should be studied more (Levy, Reuven & Shaul 2008). Itch has been also connected at least 
to Nedd4 member N4BP1 and MDM2 (Kubo et al. 2010); (Oberst 2007). Itch regulation is a 
fairly new field of research and the amount of in vivo studies is small. More studies should be 
done to evaluate its possible role in cancer treatment. Luckily successful in vitro studies give 
a good stepping stone for in vivo research and towards more efficient clinical trials. 
Adenovirus-mediated transfer of p73 has shown good results in vitro but also in vivo (Tuve 
2006) but the possible problems connected to virus-mediated gene therapy (innate-immune 
responses, off-target effects) may become problematic in clinical treatment (Couto, High 
2010). PPIG3-DNA dendrimer nanoparticles have been seen as a more safe option for future 
gene therapies (Chisholm et al. 2009). They could be used as direct p73 gene transfer or as 
indirect e.g. in siRNA/shRNA-mediated Itch knockdown. Targeting towards specific p73 
isoforms (transactivating TA or dominant-negative ΔN isoforms) could also be effective way 
to enhance apoptosis and cell cycle arrest in cancer cells, if only a validated way of isoform 
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regulation could be found. The network surrounding p73 is extensive, consisting of several 
regulators and inhibitors (Tozluoǧlu et al. 2008). This indicates that there is a considerable 
number of possible therapeutic targets, which may offer options for future cancer therapy. 
 
 
 
 
 
 
 
 
 
 
  
35 
 
 
8 REFERENCES 
 
  
Agami, R., Blandino, G., Oren, M. & Shaul, Y. 1999, "Interaction of c-Abl and p73alpha and 
their collaboration to induce apoptosis", Nature, vol. 399, no. 6738, pp. 809-813.  
Agostini, M., Tucci, P., Chen, H., Knight, R.A., Bano, D., Nicotera, P., McKeon, F. & 
Melino, G. 2010, "P73 Regulates Maintenance of Neural Stem Cell", Biochemical and 
biophysical research communications, vol. 403, no. 1, pp. 13-17.  
Ambros, V., Lee, R.C., Lavanway, A., Williams, P.T. & Jewell, D. 2003, "MicroRNAs and 
other tiny endogenous RNAs in C. elegans", Current biology : CB, vol. 13, no. 10, pp. 
807-818.  
Ambrosini, G., Sambol, E.B., Carvajal, D., Vassilev, L.T., Singer, S. & Schwartz, G.K. 2007, 
"Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis 
in cancer cells with mutant p53 by activating E2F1", Oncogene, vol. 26, no. 24, pp. 
3473-3481.  
Balint, E., Bates, S. & Vousden, K.H. 1999, "Mdm2 binds p73 alpha without targeting 
degradation", Oncogene, vol. 18, no. 27, pp. 3923-3929.  
Bell, L.A. & Ryan, K.M. 2004, "Life and death decisions by E2F-1", Cell death and 
differentiation, vol. 11, no. 2, pp. 137-142.  
Bergamaschi, D., Samuels, Y., Jin, B., Duraisingham, S., Crook, T. & Lu, X. 2004, "ASPP1 
and ASPP2: common activators of p53 family members", Molecular and cellular 
biology, vol. 24, no. 3, pp. 1341-1350.  
Bergamaschi, D., Samuels, Y., O'Neil, N.J., Trigiante, G., Crook, T., Hsieh, J.K., O'Connor, 
D.J., Zhong, S., Campargue, I., Tomlinson, M.L., Kuwabara, P.E. & Lu, X. 2003, 
"iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human", Nature 
genetics, vol. 33, no. 2, pp. 162-167.  
Bitomsky, N. 2009, "Apoptosis and autophagy: Regulation of apoptosis by DNA damage 
signalling - roles of p53, p73 and HIPK2", FEBS JOURNAL, vol. 276, no. 21, pp. 6074-
6083.  
Casciano, I., Mazzocco, K., Boni, L., Pagnan, G., Banelli, B., Allemanni, G., Ponzoni, M., 
Tonini, G.P. & Romani, M. 2002, "Expression of DeltaNp73 is a molecular marker for 
adverse outcome in neuroblastoma patients", Cell death and differentiation, vol. 9, no. 3, 
pp. 246-251.  
Chakraborty, J. 2010, "Gain of cellular adaptation due to prolonged p53 impairment leads to 
functional switchover from p53 to p73 during DNA damage in acute myeloid leukemia 
cells", Journal of Biological Chemistry, vol. 285, no. 43, pp. 33104-12.  
Chi, S.W., Ayed, A. & Arrowsmith, C.H. 1999, "Solution structure of a conserved C-terminal 
domain of p73 with structural homology to the SAM domain", The EMBO journal, vol. 
18, no. 16, pp. 4438-4445.  
Chisholm, E.J., Vassaux, G., Martin-Duque, P., Chevre, R., Lambert, O., Pitard, B., Merron, 
A., Weeks, M., Burnet, J., Peerlinck, I., Dai, M.S., Alusi, G., Mather, S.J., Bolton, K., 
Uchegbu, I.F., Schatzlein, A.G. & Baril, P. 2009, "Cancer-specific transgene expression 
mediated by systemic injection of nanoparticles", Cancer research, vol. 69, no. 6, pp. 
2655-2662.  
Choi, H.R., Batsakis, J.G., Zhan, F., Sturgis, E., Luna, M.A. & El-Naggar, A.K. 2002, 
"Differential expression of p53 gene family members p63 and p73 in head and neck 
squamous tumorigenesis", Human pathology, vol. 33, no. 2, pp. 158-164.  
36 
 
Concin, N., Becker, K., Slade, N., Erster, S., Mueller-Holzner, E., Ulmer, H., Daxenbichler, 
G., Zeimet, A., Zeillinger, R., Marth, C. & Moll, U.M. 2004, "Transdominant 
DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their 
role as epigenetic p53 inhibitors in vivo", Cancer research, vol. 64, no. 7, pp. 2449-2460.  
Concin, N., Hofstetter, G., Berger, A., Gehmacher, A., Reimer, D., Watrowski, R., Tong, D., 
Schuster, E., Hefler, L., Heim, K., Mueller-Holzner, E., Marth, C., Moll, U.M., Zeimet, 
A.G. & Zeillinger, R. 2005, "Clinical relevance of dominant-negative p73 isoforms for 
responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial 
p53-p73 cross-talk in vivo", Clinical cancer research : an official journal of the 
American Association for Cancer Research, vol. 11, no. 23, pp. 8372-8383.  
Coppola, D., Parikh, V., Boulware, D. & Blanck, G. 2009, "Substantially reduced expression 
of PIAS1 is associated with colon cancer development", Journal of cancer research and 
clinical oncology, vol. 135, no. 9, pp. 1287-1291.  
Couto, L.B. & High, K.A. 2010, "Viral vector-mediated RNA interference", Current opinion 
in pharmacology, vol. 10, no. 5, pp. 534-542.  
Das, S. 2006, "Therapeutic potential of an adenovirus expressing p73 beta, a p53 homologue, 
against human papilloma virus positive cervical cancer in vitro and in vivo", Cancer 
Biology & Therapy, vol. 5, no. 2, pp. 210-7.  
De Laurenzi, V., Costanzo, A., Barcaroli, D., Terrinoni, A., Falco, M., Annicchiarico-
Petruzzelli, M., Levrero, M. & Melino, G. 1998, "Two new p73 splice variants, gamma 
and delta, with different transcriptional activity", The Journal of experimental medicine, 
vol. 188, no. 9, pp. 1763-1768.  
Dominguez, G., Garcia, J.M., Pena, C., Silva, J., Garcia, V., Martinez, L., Maximiano, C., 
Gomez, M.E., Rivera, J.A., Garcia-Andrade, C. & Bonilla, F. 2006, "DeltaTAp73 
upregulation correlates with poor prognosis in human tumors: putative in vivo network 
involving p73 isoforms, p53, and E2F-1", Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology, vol. 24, no. 5, pp. 805-815.  
Dong, Y.B., Yang, H.L., Elliott, M.J. & McMasters, K.M. 2002, "Adenovirus-mediated E2F-
1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II 
inhibitors", Cancer research, vol. 62, no. 6, pp. 1776-1783.  
Dulloo, I., Gopalan, G., Melino, G. & Sabapathy, K. 2010, "The antiapoptotic DeltaNp73 is 
degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-
mediated pathway", Proceedings of the National Academy of Sciences of the United 
States of America, vol. 107, no. 11, pp. 4902-4907.  
Emmrich, S., Wang, W., John, K., Li, W. & Putzer, B.M. 2009, "Antisense gapmers 
selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth 
in vivo", Molecular cancer, vol. 8, pp. 61.  
Endo, S., Yamato, K., Hirai, S., Moriwaki, T., Fukuda, K., Suzuki, H., Abei, M., Nakagawa, I. 
& Hyodo, I. 2011, "Potent in vitro and in vivo antitumor effects of MDM2 inhibitor 
nutlin-3 in gastric cancer cells", Cancer science, vol. 102, no. 3, pp. 605-613.  
Faridoni-Laurens, L., Tourpin, S., Alsafadi, S., Barrois, M., Temam, S., Janot, F., Koscielny, 
S., Bosq, J., Benard, J. & Ahomadegbe, J.C. 2008, "Involvement of N-terminally 
truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a 
comparison with p53 mutations", Cell cycle (Georgetown, Tex.), vol. 7, no. 11, pp. 1587-
1596.  
Flinterman, M. 2005, "E1A activates transcription of p73 and Noxa to induce apoptosis", 
Journal of Biological Chemistry, vol. 280, no. 7, pp. 5945-59.  
Flores, E.R., Tsai, K.Y., Crowley, D., Sengupta, S., Yang, A., McKeon, F. & Jacks, T. 2002, 
"p63 and p73 are required for p53-dependent apoptosis in response to DNA damage", 
Nature, vol. 416, no. 6880, pp. 560-564.  
37 
 
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T. & Prives, C. 2001, "A subset of tumor-derived 
mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the 
p53 core domain", Molecular and cellular biology, vol. 21, no. 5, pp. 1874-1887.  
Grob, T.J., Novak, U., Maisse, C., Barcaroli, D., Luthi, A.U., Pirnia, F., Hugli, B., Graber, 
H.U., De Laurenzi, V., Fey, M.F., Melino, G. & Tobler, A. 2001, "Human delta Np73 
regulates a dominant negative feedback loop for TAp73 and p53", Cell death and 
differentiation, vol. 8, no. 12, pp. 1213-1223.  
Guan, Y.S., Liu, Y., He, Q., Li, X., Yang, L., Hu, Y. & La, Z. 2011, "p53 gene therapy in 
combination with transcatheter arterial chemoembolization for HCC: One-year follow-
up", World journal of gastroenterology : WJG, vol. 17, no. 16, pp. 2143-2149.  
Han, S., Semba, S., Abe, T., Makino, N., Furukawa, T., Fukushige, S., Takahashi, H., 
Sakurada, A., Sato, M., Shiiba, K., Matsuno, S., Nimura, Y., Nakagawara, A. & Horii, A. 
1999, "Infrequent somatic mutations of the p73 gene in various human cancers", 
European journal of surgical oncology : the journal of the European Society of Surgical 
Oncology and the British Association of Surgical Oncology, vol. 25, no. 2, pp. 194-198.  
Hansen, T.M., Rossi, M., Roperch, J.P., Ansell, K., Simpson, K., Taylor, D., Mathon, N., 
Knight, R.A. & Melino, G. 2007, "Itch inhibition regulates chemosensitivity in vitro", 
Biochemical and biophysical research communications, vol. 361, no. 1, pp. 33-36.  
Helgason, G.V., O'Prey, J. & Ryan, K.M. 2010, "Oncogene-induced sensitization to 
chemotherapy-induced death requires induction as well as deregulation of E2F1", 
Cancer research, vol. 70, no. 10, pp. 4074-4080.  
Holcakova, J. 2008, "The cell type-specific effect of TAp73 isoforms on the cell cycle and 
apoptosis", Cellular & Molecular Biology Letters, vol. 13, no. 3, pp. 404-420.  
Hollstein, M., Rice, K., Greenblatt, M.S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-
Sorensen, B., Montesano, R. & Harris, C.C. 1994, "Database of p53 gene somatic 
mutations in human tumors and cell lines", Nucleic acids research, vol. 22, no. 17, pp. 
3551-3555.  
Hong, S.M., Cho, H., Moskaluk, C.A., Yu, E. & Zaika, A.I. 2007, "P63 and P73 Expression 
in Extrahepatic Bile Duct Carcinoma and their Clinical Significance", Journal of 
molecular histology, vol. 38, no. 3, pp. 167-175.  
Huqun, Endo, Y., Xin, H., Takahashi, M., Nukiwa, T. & Hagiwara, K. 2003, "A naturally 
occurring p73 mutation in a p73-p53 double-mutant lung cancer cell line encodes p73 
alpha protein with a dominant-negative function", Cancer science, vol. 94, no. 8, pp. 
718-724.  
Iacono, M.L., Monica, V., Saviozzi, S., Ceppi, P., Bracco, E., Papotti, M. & Scagliotti, G.V. 
2011, "P63 and P73 Isoform Expression in Non-Small Cell Lung Cancer and 
Corresponding Morphological Normal Lung Tissue", Journal of thoracic oncology : 
official publication of the International Association for the Study of Lung Cancer, vol. 6, 
no. 3, pp. 473-481.  
Ishimoto, O., Kawahara, C., Enjo, K., Obinata, M., Nukiwa, T. & Ikawa, S. 2002, "Possible 
oncogenic potential of DeltaNp73: a newly identified isoform of human p73", Cancer 
research, vol. 62, no. 3, pp. 636-641.  
John, K., Alla, V., Meier, C. & Putzer, B.M. 2010, "GRAMD4 mimics p53 and mediates the 
apoptotic function of p73 at mitochondria", Cell death and differentiation, .  
Jones, E.V., Dickman, M.J. & Whitmarsh, A.J. 2007, "Regulation of p73-mediated apoptosis 
by c-Jun N-terminal kinase", The Biochemical journal, vol. 405, no. 3, pp. 617-623.  
Jost, C.A., Marin, M.C. & Kaelin, W.G.,Jr 1997, "P73 is a Simian [Correction of Human] 
P53-Related Protein that can Induce Apoptosis", Nature, vol. 389, no. 6647, pp. 191-194.  
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.C., Valent, A., Minty, A., Chalon, 
P., Lelias, J.M., Dumont, X., Ferrara, P., McKeon, F. & Caput, D. 1997, 
38 
 
"Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in 
neuroblastoma and other human cancers", Cell, vol. 90, no. 4, pp. 809-819.  
Killick, R., Niklison-Chirou, M., Tomasini, R., Bano, D., Rufini, A., Grespi, F., Velletri, T., 
Tucci, P., Sayan, B.S., Conforti, F., Gallagher, E., Nicotera, P., Mak, T.W., Melino, G., 
Knight, R.A. & Agostini, M. 2011, "P73: a Multifunctional Protein in Neurobiology", 
Molecular neurobiology, vol. 43, no. 2, pp. 139-146.  
Klanrit, P., Flinterman, M.B., Odell, E.W., Melino, G., Killick, R., Norris, J.S. & Tavassoli, 
M. 2008, "Specific isoforms of p73 control the induction of cell death induced by the 
viral proteins, E1A or apoptin", Cell cycle (Georgetown, Tex.), vol. 7, no. 2, pp. 205-215.  
Koeppel, M., van Heeringen, S.J., Kramer, D., Smeenk, L., Janssen-Megens, E., Hartmann, 
M., Stunnenberg, H.G. & Lohrum, M. 2011, "Crosstalk between c-Jun and 
TAp73{alpha}/{beta} contributes to the apoptosis-survival balance", Nucleic acids 
research, .  
Kontaki, H. & Talianidis, I. 2010, "Lysine methylation regulates E2F1-induced cell death", 
Molecular cell, vol. 39, no. 1, pp. 152-160.  
Kotaja, N., Karvonen, U., Janne, O.A. & Palvimo, J.J. 2002, "PIAS proteins modulate 
transcription factors by functioning as SUMO-1 ligases", Molecular and cellular biology, 
vol. 22, no. 14, pp. 5222-5234.  
Kubo, N., Okoshi, R., Nakashima, K., Shimozato, O., Nakagawara, A. & Ozaki, T. 2010, 
"MDM2 promotes the proteasomal degradation of p73 through the interaction with Itch 
in HeLa cells", Biochemical and biophysical research communications, vol. 403, no. 3-4, 
pp. 405-411.  
Lau, L.M., Nugent, J.K., Zhao, X. & Irwin, M.S. 2008, "HDM2 antagonist Nutlin-3 disrupts 
p73-HDM2 binding and enhances p73 function", Oncogene, vol. 27, no. 7, pp. 997-1003.  
Lefkimmiatis, K., Caratozzolo, M.F., Merlo, P., D'Erchia, A.M., Navarro, B., Levrero, M., 
Sbisa', E. & Tullo, A. 2009, "P73 and P63 Sustain Cellular Growth by Transcriptional 
Activation of Cell Cycle Progression Genes", Cancer research, vol. 69, no. 22, pp. 
8563-8571.  
Levrero, M., De Laurenzi, V., Costanzo, A., Gong, J., Wang, J.Y. & Melino, G. 2000, "The 
p53/p63/p73 family of transcription factors: overlapping and distinct functions", Journal 
of cell science, vol. 113 ( Pt 10), no. Pt 10, pp. 1661-1670.  
Levy, D. 2007, "The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated 
ubiquitination of p73", Cell Death & Differentiation, vol. 14, no. 4, pp. 743-51.  
Levy, D., Reuven, N. & Shaul, Y. 2008, "A regulatory circuit controlling Itch-mediated p73 
degradation by Runx", The Journal of biological chemistry, vol. 283, no. 41, pp. 27462-
27468.  
Lin, Y.L. 2009, "p63 and p73 transcriptionally regulate genes involved in DNA repair", PLoS 
Genetics, vol. 5, no. 10, pp. e1000680.  
Liu, S.S., Chan, K.Y., Cheung, A.N., Liao, X.Y., Leung, T.W. & Ngan, H.Y. 2006, 
"Expression of deltaNp73 and TAp73alpha independently associated with 
radiosensitivities and prognoses in cervical squamous cell carcinoma", Clinical cancer 
research : an official journal of the American Association for Cancer Research, vol. 12, 
no. 13, pp. 3922-3927.  
Lohr, N.J., Molleston, J.P., Strauss, K.A., Torres-Martinez, W., Sherman, E.A., Squires, R.H., 
Rider, N.L., Chikwava, K.R., Cummings, O.W., Morton, D.H. & Puffenberger, E.G. 
2010, "Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem 
autoimmune disease", American Journal of Human Genetics, vol. 86, no. 3, pp. 447-453.  
Mai, M., Yokomizo, A., Qian, C., Yang, P., Tindall, D.J., Smith, D.I. & Liu, W. 1998, 
"Activation of p73 silent allele in lung cancer", Cancer research, vol. 58, no. 11, pp. 
2347-2349.  
39 
 
Martin, A.G., Trama, J., Crighton, D., Ryan, K.M. & Fearnhead, H.O. 2009, "Activation of 
p73 and induction of Noxa by DNA damage requires NF-kappa B", Aging, vol. 1, no. 3, 
pp. 335-349.  
Melino, G., Bernassola, F., Ranalli, M., Yee, K., Zong, W.X., Corazzari, M., Knight, R.A., 
Green, D.R., Thompson, C. & Vousden, K.H. 2004, "p73 Induces apoptosis via PUMA 
transactivation and Bax mitochondrial translocation", The Journal of biological 
chemistry, vol. 279, no. 9, pp. 8076-8083.  
Melino, G., Gallagher, E., Aqeilan, R.I., Knight, R., Peschiaroli, A., Rossi, M., Scialpi, F., 
Malatesta, M., Zocchi, L., Browne, G., Ciechanover, A. & Bernassola, F. 2008, "Itch: a 
HECT-type E3 ligase regulating immunity, skin and cancer", Cell death and 
differentiation, vol. 15, no. 7, pp. 1103-1112.  
Muller, M. 2005, "TAp73/Delta Np73 influences apoptotic response, chemosensitivity and 
prognosis in hepatocellular carcinoma", Cell Death & Differentiation, vol. 12, no. 12, pp. 
1564-77.  
Muller, M., Schleithoff, E.S., Stremmel, W., Melino, G., Krammer, P.H. & Schilling, T. 2006, 
"One, two, three--p53, p63, p73 and chemosensitivity", Drug resistance updates : 
reviews and commentaries in antimicrobial and anticancer chemotherapy, vol. 9, no. 6, 
pp. 288-306.  
Munarriz, E., Barcaroli, D., Stephanou, A., Townsend, P.A., Maisse, C., Terrinoni, A., Neale, 
M.H., Martin, S.J., Latchman, D.S., Knight, R.A., Melino, G. & De Laurenzi, V. 2004, 
"PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of 
p73", Molecular and cellular biology, vol. 24, no. 24, pp. 10593-10610.  
Naka, M., Ozaki, T., Takada, N., Takahashi, M., Shishikura, T., Sakiyama, S., Tada, M., 
Todo, S. & Nakagawara, A. 2001, "Functional characterization of naturally occurring 
mutants (P405R and P425L) of p73alpha and p73beta found in neuroblastoma and lung 
cancer", Oncogene, vol. 20, no. 27, pp. 3568-3572.  
Nakano, K. & Vousden, K.H. 2001, "PUMA, a novel proapoptotic gene, is induced by p53", 
Molecular cell, vol. 7, no. 3, pp. 683-694.  
Nekulova, M., Zitterbart, K., Sterba, J. & Veselska, R. 2010, "Analysis of the intracellular 
localization of p73 N-terminal protein isoforms TAp73 and Np73 in medulloblastoma 
cell lines", Journal of molecular histology, vol. 41, no. 4-5, pp. 267-275.  
Nemajerova, A. 2009, "Targeted deletion of p73 in mice reveals its role in T cell 
development and lymphomagenesis", PLoS ONE [Electronic Resource], vol. 4, no. 11, 
pp. e7784.  
Ng, S.W., Yiu, G.K., Liu, Y., Huang, L.W., Palnati, M., Jun, S.H., Berkowitz, R.S. & Mok, 
S.C. 2000, "Analysis of p73 in human borderline and invasive ovarian tumor", Oncogene, 
vol. 19, no. 15, pp. 1885-1890.  
Nomoto, S., Haruki, N., Kondo, M., Konishi, H., Takahashi, T., Takahashi, T. & Takahashi, 
T. 1998, "Search for mutations and examination of allelic expression imbalance of the 
p73 gene at 1p36.33 in human lung cancers", Cancer research, vol. 58, no. 7, pp. 1380-
1383.  
Oberst, A. 2007, "The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 
ligase Itch", Proceedings of the National Academy of Sciences of the United States of 
America, vol. 104, no. 27, pp. 11280-5.  
Ongkeko, W.M., Wang, X.Q., Siu, W.Y., Lau, A.W., Yamashita, K., Harris, A.L., Cox, L.S. 
& Poon, R.Y. 1999, "MDM2 and MDMX bind and stabilize the p53-related protein p73", 
Current biology : CB, vol. 9, no. 15, pp. 829-832.  
Ozaki, T. 2009, "Deregulated expression of E2F1 promotes proteolytic degradation of tumor 
suppressor p73 and inhibits its transcriptional activity", Biochemical and biophysical 
research communications, vol. 387, no. 1, pp. 143-148.  
40 
 
Perry, W.L., Hustad, C.M., Swing, D.A., O'Sullivan, T.N., Jenkins, N.A. & Copeland, N.G. 
1998, "The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H 
mice", Nature genetics, vol. 18, no. 2, pp. 143-146.  
Petrenko, O., Zaika, A. & Moll, U.M. 2003, "deltaNp73 facilitates cell immortalization and 
cooperates with oncogenic Ras in cellular transformation in vivo", Molecular and 
cellular biology, vol. 23, no. 16, pp. 5540-5555.  
Puig, P., Capodieci, P., Drobnjak, M., Verbel, D., Prives, C., Cordon-Cardo, C. & Di Como, 
C.J. 2003, "p73 Expression in human normal and tumor tissues: loss of p73alpha 
expression is associated with tumor progression in bladder cancer", Clinical cancer 
research : an official journal of the American Association for Cancer Research, vol. 9, 
no. 15, pp. 5642-5651.  
Ray, R.M. 2011, "Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer 
cells by activating p73-and E2F1-mediated expression of PUMA and Siva-1", 
APOPTOSIS, vol. 16, no. 1, pp. 35-44.  
Robinson, R.A., Lu, X., Jones, E.Y. & Siebold, C. 2008, "Biochemical and structural studies 
of ASPP proteins reveal differential binding to p53, p63, and p73", Structure (London, 
England : 1993), vol. 16, no. 2, pp. 259-268.  
Rocco, J.W., Leong, C.O., Kuperwasser, N., DeYoung, M.P. & Ellisen, L.W. 2006, "P63 
Mediates Survival in Squamous Cell Carcinoma by Suppression of P73-Dependent 
Apoptosis", Cancer cell, vol. 9, no. 1, pp. 45-56.  
Rodicker, F., Stiewe, T., Zimmermann, S. & Putzer, B.M. 2001, "Therapeutic efficacy of 
E2F1 in pancreatic cancer correlates with TP73 induction", Cancer research, vol. 61, no. 
19, pp. 7052-7055.  
Roperch, J.P. 2008, "Netrin-1 induces apoptosis in human cervical tumor cells via the 
TAp73alpha tumor suppressor", Cancer research, vol. 68, no. 20, pp. 8231-9.  
Rosenbluth, J.M. 2009, "Evaluation of p63 and p73 antibodies for cross-reactivity", Cell 
Cycle, vol. 8, no. 22, pp. 3702-6.  
Rossi, M. 2006, "The E3 ubiquitin ligase Itch controls the protein stability of p63", 
Proceedings of the National Academy of Sciences of the United States of America, vol. 
103, no. 34, pp. 12753-12758.  
Rossi, M., De Laurenzi, V., Munarriz, E., Green, D.R., Liu, Y.C., Vousden, K.H., Cesareni, 
G. & Melino, G. 2005, "The ubiquitin-protein ligase Itch regulates p73 stability", The 
EMBO journal, vol. 24, no. 4, pp. 836-848.  
Sampath, D., Calin, G.A., Puduvalli, V.K., Gopisetty, G., Taccioli, C., Liu, C.G., Ewald, B., 
Liu, C., Keating, M.J. & Plunkett, W. 2009, "Specific activation of microRNA106b 
enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the 
ubiquitin ligase Itch for degradation", Blood, vol. 113, no. 16, pp. 3744-3753.  
Sasaki, Y., Morimoto, I., Ishida, S., Yamashita, T., Imai, K. & Tokino, T. 2001, "Adenovirus-
mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and 
apoptosis in colorectal cancer cell lines: potential application to gene therapy of 
colorectal cancer", Gene therapy, vol. 8, no. 18, pp. 1401-1408.  
Sauer, M., Bretz, A.C., Beinoraviciute-Kellner, R., Beitzinger, M., Burek, C., Rosenwald, A., 
Harms, G.S. & Stiewe, T. 2008, "C-terminal diversity within the p53 family accounts for 
differences in DNA binding and transcriptional activity", Nucleic acids research, vol. 36, 
no. 6, pp. 1900-1912.  
Sayan, B.S. 2010, "Differential control of TAp73 and DeltaNp73 protein stability by the ring 
finger ubiquitin ligase PIR2", Proceedings of the National Academy of Sciences of the 
United States of America, vol. 107, no. 29, pp. 12877-82.  
41 
 
Schuster, A. 2010, "Delta Np73 beta is oncogenic in hepatocellular carcinoma by blocking 
apoptosis signaling via death receptors and mitochondria", CELL CYCLE, vol. 9, no. 13, 
pp. 2629-2639.  
Seitz, S.J., Schleithoff, E.S., Koch, A., Schuster, A., Teufel, A., Staib, F., Stremmel, W., 
Melino, G., Krammer, P.H., Schilling, T. & Muller, M. 2010, "Chemotherapy-induced 
apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the 
extrinsic and the intrinsic pathway", International journal of cancer.Journal 
international du cancer, vol. 126, no. 9, pp. 2049-2066.  
Senoo, M., Manis, J.P., Alt, F.W. & McKeon, F. 2004, "p63 and p73 are not required for the 
development and p53-dependent apoptosis of T cells", Cancer cell, vol. 6, no. 1, pp. 85-
89. 
 St.Rosemary Educational Institution. Mitosis and the Cell Cycle, SchoolWorkHelper. 
Available: http://schoolworkhelper.net/2010/06/mitosis-and-the-cell-cycle/ [6/20/2011]. 
Stiewe, T. 2007, "The p53 family in differentiation and tumorigenesis", Nature 
reviews.Cancer, vol. 7, no. 3, pp. 165-168.  
Stiewe, T. & Putzer, B.M. 2000, "Role of the p53-homologue p73 in E2F1-induced 
apoptosis", Nature genetics, vol. 26, no. 4, pp. 464-469.  
Strano, S., Munarriz, E., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A.J., 
Sacchi, A., Cesareni, G., Oren, M. & Blandino, G. 2000, "Physical and functional 
interaction between p53 mutants and different isoforms of p73", The Journal of 
biological chemistry, vol. 275, no. 38, pp. 29503-29512.  
Sun, Q. 2009, "PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head 
and neck cancer cells", Oncogene, vol. 28, no. 24, pp. 2348-2357.  
Takahashi, H., Ichimiya, S., Nimura, Y., Watanabe, M., Furusato, M., Wakui, S., Yatani, R., 
Aizawa, S. & Nakagawara, A. 1998, "Mutation, allelotyping, and transcription analyses 
of the p73 gene in prostatic carcinoma", Cancer research, vol. 58, no. 10, pp. 2076-2077.  
Tannapfel, A., John, K., Mise, N., Schmidt, A., Buhlmann, S., Ibrahim, S.M. & Putzer, B.M. 
2008, "Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the 
p53 family inhibitor DNp73", Carcinogenesis, vol. 29, no. 1, pp. 211-218.  
Tomasini, R. 2008, "TAp73 knockout shows genomic instability with infertility and tumor 
suppressor functions", Genes & development, vol. 22, no. 19, pp. 2677-91.  
Tozluoǧlu, M., Karaca, E., Haliloglu, T. & Nussinov, R. 2008, "Cataloging and organizing 
p73 interactions in cell cycle arrest and apoptosis", Nucleic acids research, vol. 36, no. 
15, pp. 5033-5049.  
Tuve, S. 2006, "Adenovirus-mediated TA-p73beta gene transfer increases chemosensitivity 
of human malignant melanomas", Apoptosis, vol. 11, no. 2, pp. 235-43.  
Uramoto, H., Sugio, K., Oyama, T., Nakata, S., Ono, K., Morita, M., Funa, K. & Yasumoto, 
K. 2004, "Expression of deltaNp73 predicts poor prognosis in lung cancer", Clinical 
cancer research : an official journal of the American Association for Cancer Research, 
vol. 10, no. 20, pp. 6905-6911.  
Urist, M., Tanaka, T., Poyurovsky, M.V. & Prives, C. 2004, "p73 induction after DNA 
damage is regulated by checkpoint kinases Chk1 and Chk2", Genes & development, vol. 
18, no. 24, pp. 3041-3054.  
Vilgelm, A.E., Hong, S.M., Washington, M.K., Wei, J., Chen, H., El-Rifai, W. & Zaika, A. 
2010a, "Characterization of DeltaNp73 expression and regulation in gastric and 
esophageal tumors", Oncogene, vol. 29, no. 43, pp. 5861-5868.  
Vilgelm, A.E., Washington, M.K., Wei, J., Chen, H., Prassolov, V.S. & Zaika, A.I. 2010b, 
"Interactions of the p53 protein family in cellular stress response in gastrointestinal 
tumors", Molecular cancer therapeutics, vol. 9, no. 3, pp. 693-705.  
42 
 
Waltermann, A. 2003, "Differential regulation of p63 and p73 expression", Oncogene, vol. 22, 
no. 36, pp. 5686-93.  
Wang, X., Wang, J. & Jiang, X. 2011, "MdmX is essential for Mdm2-mediated p53 
polyubiquitination", The Journal of biological chemistry, .  
Weber, A., Langhanki, L., Schutz, A., Gerstner, A., Bootz, F., Wittekind, C. & Tannapfel, A. 
2002, "Expression profiles of p53, p63, and p73 in benign salivary gland tumors", 
Virchows Archiv : an international journal of pathology, vol. 441, no. 5, pp. 428-436.  
Wilhelm, M.T., Rufini, A., Wetzel, M.K., Tsuchihara, K., Inoue, S., Tomasini, R., Itie-
Youten, A., Wakeham, A., Arsenian-Henriksson, M., Melino, G., Kaplan, D.R., Miller, 
F.D. & Mak, T.W. 2010, "Isoform-specific p73 knockout mice reveal a novel role for 
delta Np73 in the DNA damage response pathway", Genes & development, vol. 24, no. 6, 
pp. 549-560.  
Willis, A.C., Pipes, T., Zhu, J. & Chen, X. 2003, "P73 can Suppress the Proliferation of Cells 
that Express Mutant P53", Oncogene, vol. 22, no. 35, pp. 5481-5495.  
Xie, Q., Bai, Y., Wu, J., Sun, Y., Wang, Y., Zhang, Y., Mei, P. & Yuan, Z. 2011, 
"Methylation-mediated regulation of E2F1 in DNA damage-induced cell death", Journal 
of receptor and signal transduction research, vol. 31, no. 2, pp. 139-146.  
Yao, J.Y. & Chen, J.K. 2010, "TAp63 plays compensatory roles in p53-deficient cancer cells 
under genotoxic stress", Biochemical and biophysical research communications, vol. 
403, no. 3-4, pp. 310-315.  
Yoshikawa, H., Nagashima, M., Khan, M.A., McMenamin, M.G., Hagiwara, K. & Harris, 
C.C. 1999, "Mutational analysis of p73 and p53 in human cancer cell lines", Oncogene, 
vol. 18, no. 22, pp. 3415-3421.  
Yuan, Z.M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y.Y., Lu, H., Kharbanda, S., 
Weichselbaum, R. & Kufe, D. 1999, "p73 is regulated by tyrosine kinase c-Abl in the 
apoptotic response to DNA damage", Nature, vol. 399, no. 6738, pp. 814-817.  
Zaika, A.I., Slade, N., Erster, S.H., Sansome, C., Joseph, T.W., Pearl, M., Chalas, E. & Moll, 
U.M. 2002, "ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is 
Up-regulated in Human Tumors", The Journal of experimental medicine, vol. 196, no. 6, 
pp. 765-780.  
Zeng, X., Chen, L., Jost, C.A., Maya, R., Keller, D., Wang, X., Kaelin, W.G.,Jr, Oren, M., 
Chen, J. & Lu, H. 1999, "MDM2 suppresses p73 function without promoting p73 
degradation", Molecular and cellular biology, vol. 19, no. 5, pp. 3257-3266.  
Zhu, J., Jiang, J., Zhou, W. & Chen, X. 1998, "The potential tumor suppressor p73 
differentially regulates cellular p53 target genes", Cancer research, vol. 58, no. 22, pp. 
5061-5065.  
 
  
   
 
 
 
 
 
 
 
 
EXPERIMENTAL PART: 
THE ROLE OF P73 AND ITCH 
IN PANCREATIC CANCER CELLS 
 
 
 
 
 
 
 
 
 
   
 
TABLE OF CONTENTS 
 
1 INTRODUCTION ....................................................................................................................... 1 
2 THE AIM OF THE STUDY ........................................................................................................ 1 
3 PANCREATIC CANCER AS A TARGET FOR EFFECTIVE CANCER THERAPY ............. 2 
4 MATERIALS AND METHODS ................................................................................................. 3 
4.1. Transfection of B16F10 cell line with DAB16 dendrimers ...................................................... 3 
4.2. Size measurement of the complex (DAB16 N/P30) ................................................................. 3 
4.3. Transfection efficacy with different buffers and mediums to cell lines A431 and MDAMB 
231 .................................................................................................................................................... 4 
4.4. Transfection and cytotoxicity assays in pancreatic cancer cells ............................................... 4 
4.5. Protein level measurements of p73 and Itch ............................................................................. 5 
5 RESULTS .................................................................................................................................... 5 
5.1. DAB16 transfection of B16F10 cell line .................................................................................. 5 
5.2. Size of the complex ................................................................................................................... 6 
5.3. Comparison of the transfection efficacy with different buffers and mediums ......................... 7 
5.4. Transfection and cytotoxicity of DAB16 N/P30 in pancreatic cancer cells ............................. 8 
5.5. Western blot for Itch and p73 ................................................................................................. 15 
6 DISCUSSION ............................................................................................................................ 17 
7 REFERENCES........................................................................................................................... 18 
 
APPENDIXES 
APPENDIX 1 Cell culture mediums 
APPENDIX 2 Protocol for the preparation of the complex  
APPENDIX 3 Protocol for the transfection, β-galactosidase analysis and MTT-assay  
APPENDIX 4 Protocol for protein extraction  
APPENDIX 5 Protocol for Western blotting  
APPENDIX 6 Data-files
  
1 
 
1 INTRODUCTION 
 
p73 is a member of p53 family of tumor suppressors, consisting of p53, p63 and p73 (Kaghad et al. 
1997). The p53-family members are connected to several functions in cell cycle regulation, 
development and tumorigenesis.  p73 gene encodes a protein with similar characteristics of p53 and 
p63. The family members have similar but also individual roles (Levrero et al. 2000). p73 is 
involved in apoptosis and cell cycle arrest in cancer cells. p53 protects against the proliferation of 
damaged cells and this way decreases tumour growth. Genetic mutations of p53 appear in half of 
the human cancers, resulting as loss or inactivation of p53 (Hollstein et al. 1994). The extensive 
amount of mutations in p53 make therapeutic approach towards it difficult. Instead, p73 has been 
found to be more rarely mutated in cancers than p53 and is considered to be more viable target for 
anticancer therapy approach (Kaghad et al. 1997). 
 
One major factor regulating the levels of p63 and p73 is ubiquitin-protein isopeptide (E3) ligase 
Itch. Itch selectively binds to the protein’s PY-motif and ubiquitinates it, causing its rapid 
proteosomal degradation (Rossi 2006) ; (Rossi et al. 2005). In ubiquitination, the protein is 
inactivated by covalent attachment by one or more ubiquitin monomers. p53 does not have PY-
motif and it is negatively controlled by MDM2, not by Itch. Controlled knockdown of Itch by 
siRNA/shRNA leading to the induction of p73 levels could offer a potential therapeutic method to 
improve cancer treatment in the future. 
 
2 THE AIM OF THE STUDY 
 
The work was carried out between October 2008 and February 2009 in School of Pharmacy, 
University of London. It was done as a part of a bigger research project in which the main goal was 
to use a dendrimer nanoparticle to deliver siRNA to pancreatic cancer cells, aiming to down 
regulate Itch and as a result cancer cells to become more sensitive to anticancer drugs mediated by 
p73 upregulation. 
 
The experimental part included basic cell culture, optimizing the conditions for cancer cell 
transfection using dendrimer-complexes, measurement of cytotoxicity of the complexes, 
characterization of pancreatic cancer cell lines and measurement of Itch and p73 protein levels in 
pancreatic cancer cell lines. The cell lines used were B16F10 (melanoma cancer), A431 
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(epidermoid cancer), MDAMB 231 (breast cancer) and 4 different pancreatic cancer cells PANC1, 
BxPc-3, Mia PaCa-2 and HPAC. In protein extraction also HeLa (cervical cancer) and H1299 (non-
small cell lung carcinoma) cell lines were used as a comparison material. 
 
Similar studies have not been done before in pancreatic cancer cell lines. Itch downregulation with 
siRNA has been tested in vitro by Hansen et al. in 2007, where it was combined with 
chemotherapeutic drugs and led to enhanced p53-family mediated apoptosis in HeLa cells (Hansen 
et al. 2007). The study also showed that cells with no functional p53 (mutated or absent) were more 
sensitive to Itch down regulation, proving the role of Itch in majority of cancer having mutated p53. 
 
3 PANCREATIC CANCER AS A TARGET FOR EFFECTIVE CANCER THERAPY 
 
Pancreatic cancer is a severe disease and usually a patient is confronted with a poor prognosis, the 
overall 5-year survival rate in all pancreatic cancer stages being 5 to 6 per cent (Jemal et al. 2010). 
In a recent phase 2 trial by Mamon et al. patients with non-metastasive pancreatic cancer treated 
with gemcitabine, 5-fluorouracil and radiation therapy had overall survival rate of only 12 months 
(follow-up time 55 months) (Mamon et al. 2011). An objective tumor response was seen in 25 per 
cent of the patients.  In USA from 1990 to 2006 the death rates have grown for women having 
pancreatic cancer (Jemal et al. 2010). Early detection and screening of the disease is reasonable 
only in high risk patients (Xu, Zhang & Zhao 2011). Gemcitabine is used as a standard treatment of 
pancreatic cancer and radiotherapy is under development towards more modern radiation 
techniques, hopefully estimating better results in the future. The failure of the therapy in pancreatic 
cancer has been proposed to stem from the heterogeneous molecular pathogenesis of pancreatic 
cancers, involving several oncogenic pathways and mutations (Li, Saif 2009). More profound 
cancer treatments are needed, directing the research to explore new molecular targets and gene 
therapy. 
 
Gene therapy by adenovirus-mediated p73 upregulation has shown promising results in vitro in 
p53-null pancreatic cancer cells and supports the use of p73 in cancer treatment (Rodicker, Putzer 
2003). In vivo studies specifying the role of p73 in adenovirus-mediated gene therapy in pancreatic 
cancer have not been done so far and safety issues are associated with the use of viral vectors e.g. in 
RNA interference (off-target effects, innate immune responses) (Couto, High 2010).  
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Instead, the use of PPIG3/DNA (polypropylenimine dendrimer) nanoparticles in gene transfer has 
shown good results in in vitro but also in vivo in mice (Chisholm et al. 2009). Nanoparticles are 
proven to specifically target and accumulate in tumors after systemic injection, without having any 
transferring effect on the surrounding tissues. The nanoparticles are in a form of well-organized 
fingerprint-like structure, having DNA molecules inside. The colloidal stability is an important 
quality of nanoparticles, attained in the study of Chisholm et al. Also the expression of transgene in 
tumor had succeeded, testifying the potential use of PPIG3 nanoparticles in cancer gene therapy.  
 
4 MATERIALS AND METHODS 
 
4.1. Transfection of B16F10 cell line with DAB16 dendrimers 
 
Melanoma cancer cell line B16F10 was used for evaluating the most efficient amount of DAB16-
dendrimer complex for the transfection assays. The ratio of N/P8 and N/P30 was used and the 
complex amounts were 0,5 µg, 1 µg, 2 µg, 5 µg and 10 µg. 10 000 cancer cells per well were 
seeded to a 96-well plate and the cells were grown for 3 days in supplemented medium suitable for 
B16F10 cells (DMEM, FBS, L-glutamin). Complexes were made by the protocol (Appendix 2) and 
the dilution of the complex was in 1/10 ratio to 5% dextrose when needed. Before the transfection, 
the cells were washed with DPBS. Complexes were added to the cells and the 100 µl of medium 
(DMEM + 10 % FBS) was added to each well. Lipofectamin was a positive control of the 
transfection. Incubation time for the plates was 4 hours at 37 degrees (CO2 5 %). After the 
incubation cells were cleared from the complexes and medium and supplemented medium was 
added. Cells were grown for 2 days and analysed by β-galactosidase according to the protocol 
(Appendix 3) 
 
4.2. Size measurement of the complex (DAB16 N/P30) 
 
Size of the complex (DAB16 N/P30 + pDNA) was measured in two different mediums to optimize 
the transfection conditions. The mediums were DMEM + 10 % FBS and plain DMEM. The size of 
the complex was examined also without any medium. The complexes were made by the protocol 
(Appendix 2) and HEPES was used as a complex buffer. The measurements were done by 
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Zetasizer. The first measurement took place 15 minutes after complex formation. Then 200 µl of 
complex was added to 500 µl of both mediums and incubated for 4 hours in 37 degrees (CO2 5%). 
After incubation the second measurement was done. 
 
4.3. Transfection efficacy with different buffers and mediums to cell lines A431 and MDAMB 231 
 
The assay was done to evaluate the differences in transfection efficacy when the ratio of DAB16 
dendrimer (ratios N/P8 and N/P30) and the complex buffers and transfection mediums were 
changed (buffers HEPES and MES, mediums plain DMEM and DMEM with 10% FBS). 
Complexes and transfection were done by the protocols (Appendix 2 and 3) and after the tranfection 
the plates were incubated for 4 hours in 37 degrees (CO2 5%). After incubation the transfection 
medium was removed and the cells were washed with DPBS. The suitable medium for the both cell 
lines (Appendix 1) was added and after 2 days the transfection efficacy was analysed by β-
galactosidase (Appendix 3). 
 
4.4. Transfection and cytotoxicity assays in pancreatic cancer cells 
 
Transfection assay was done to optimize the time points after transfection and compare it with the 
cytotoxicity results. Pancreatic cancer cells (Mia PaCa-2, PANC1, HPAC and BxPc-3) were seeded 
1000 cells/well and grown for 3 days in 37 degrees (CO2 5%). Cells were transfected by the 
protocol with pDNA-dendrimer (N/P30) complex, the amount used was 1 µg (Appendix 3). 
Transfection medium was DMEM with 10 % FBS. Lipofectamin was a positive control. After 
incubation the cells were cleared from the medium, washed with DPBS and completed with every 
cell line’s specific medium (Appendix 1) Cells were grown from 1 day to 4 days. At different time 
points the transfection efficacy was analysed by β-galactosidase analysis (Appendix 3) 
 
Cytotoxicity assay’s aim was to give an explanation of what happens to cell viability after exposing 
cells to complexes and plain dendrimers and possibly for the recovering of the cells in different time 
points after transfection. All four pancreatic cancer cell lines were seeded 1000 cells/well and 
grown for 3 days in 37 degrees (CO2 5%). After 3 days, plain DAB16 dendrimer solution 
(maximum concentration 20 mg/ml) or DAB16 N/P30 complexes (maximum concentration 0,25 
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mg/ml) were added to the cells. Cells were incubated for 4 hours in 37 degrees (CO2 5%). After 
incubation the cells were cleared from the solutions and washed with DPBS. Cytotoxicity of the 
complexes and plain dendrimers was measured by MTT-assay (Appendix 3) 
 
4.5. Protein level measurements of p73 and Itch 
 
Measurement of protein levels was done by Western blotting by the procol (Appendix 5). α-actin 
was used as a positive protein control. Primary antibodies were p73 clone ER-15 (Ab-2 ER15 
mouse monoclonal antibody, Thermo Scientific) and Itch (purified mouse anti-Itch Mab, BD 
Transduction Laboratories). Dilutions for antibodies were done according to the provider’s 
instructions, p73 diluted 1:100, Itch 1:1000 and α-actin 1:500. The second antibody (goat anti-
mouse IgG (H+L) horseradish peroxidase conjugate) was diluted 1:5000. 
 
5 RESULTS 
 
5.1. DAB16 transfection of B16F10 cell line 
 
Results showed that N/P30 transfects better than N/P8 in B16F10 cell line (Figure 1). Most efficient 
amount of complex for transfection was 1 ug. There are missing few results of N/P8, because results 
were out by β-galactosidase-analysis and gave minus values. 
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Figure 7. Transfection of B16F10 cells with DAB16 N/P8 and N/P30 complex. The amount of the complex 
used was 0,5 µg, 1 µg, 2 µg, 5 µg and 10 µg. Lipofectamin was used as a control and the transfection 
efficacy was measured by β-galactosidase analysis. 
 
5.2. Size of the complex 
 
To evaluate the effect of the complex size in transfection, transfection was done in DMEM + 10% 
FBS and in plain DMEM. As seen in Table 1, the complex stays smaller in medium of DMEM + 10 
% FBS than in plain DMEM.  
 
Table 2. The average size of the complex DAB16 N/P30 without medium, in mediums DMEM + 10% FBS 
and plain DMEM. Standard deviations of the results are shown on the right side of the table. 
 Size (average) +/- 
Complex 226.2 2.2 
Complex in DMEM + 10% 
FBS 
394.8 5.5 
Complex in plain DMEM 4310.6 398.9 
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5.3. Comparison of the transfection efficacy with different buffers and mediums 
 
With cell line MDAMB 231 mistake was made (N/P30 in HEPES, DMEM with 10% FBS) and the 
results were not reliable (data not shown). Overall it was seen from the results (Figure 2 and 3) that 
transfection is more efficient with complex buffer HEPES in the medium of DMEM + 10% FBS 
than with buffer MES. Transfection efficacy was lower in DMEM with 10% FBS than in plain 
DMEM. In plain DMEM the complex was bigger (Table 1), so we could assume that using HEPES 
is better in complexes and DMEM with 10% FBS keeps the size of the complex smaller. N/P30 
seemed to be more effective in transfection than N/P8. Differences in transfection between the cell 
lines were seen, in average demonstrating better transfection in A431 cell line. 
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Figure 2. Transfection of A431 cell line with DAB16 N/P8 and N/P30. 
DMEM + 10% FBS and plain DMEM were used as transfection mediums 
and complex buffer was HEPES and MES. Transfection efficacy was 
measured by β-galactosidase analysis. 
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Figure 3. Transfection of MDAMB 231 cell line with DAB16 N/P8 and N/P30. DMEM + 10% FBS and 
plain DMEM were used as transfection mediums and complex buffer was HEPES and MES. Transfection 
efficacy was measured by β-galactosidase analysis 
 
5.4. Transfection and cytotoxicity of DAB16 N/P30 in pancreatic cancer cells 
 
Results seen in Figure 4 show, that DAB16 N/P30 transfection succeeded most after 2-3 days. Cell 
line PANC1 was transfected the most and differences between the transfection of the cell lines were 
small (except BxPc-3). BxPc-3 cell line didn’t show any transfection after 1 day and even 
Lipofectamin wasn’t able to transfect the cell line (Figure 5). After 4 days of transfection, the 
results started to show bigger error bars and results were not reliable. 
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Figure 4. Transfection efficacy of pancreatic cancer cell lines with DAB16 N/P30 
after 1-4 days. Measurement was done by β-galactosidase analysis. 
 
 
Figure 5. Transfection efficacy of pancreatic cancer cell lines with DAB16 N/P30  
after 1-4 days. Measurement was done by β-galactosidase analysis. Lipofectamin was used as a control. 
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As seen in transfection assays (Figures 4 and 5) cell line BxPc-3 was almost impossible to transfect 
and the transfection efficacy was poor. On the contrary, the cytotoxity assays showed similar results 
for BxPc-3 as for other cell lines (Figures 8 and 9) indicating the possible existence of the 
mechanisms in BxPc-3 cells which differ from other pancreatic cancer cells and interfere 
complexe’s way to the nucleus. Results of the PANC1 and HPAC didn’t succeed as well as the 
others, showing more standard deviation in the values (Figures 11 and 13). Specific results of the 
cytotoxicity for each cell line are seen in Figures 6-13. IC50-values (Table 2) show recovering of 
the cell survival in 3 days post-incubation compared to 1 day post-incubation values. 
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Figure 6. Cell viability (%) and IC50 values of Mia PaCa-3 cells after the dendrimer 
solution (concentrations mg/ml) was added (measured the first (black line) and third  
(red line) day). Cell viability was analysed by MTT-assay. 
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Figure 7. Cell viability (%) and IC50 values of Mia PaCa-3 cells after the complex 
solution (concentrations mg/ml (not ug/ml)) was added and measured the first  
(black line) and third (red line) day. Cell viability was analysed by MTT-assay. 
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Figure 8. Cell viability (%) and IC50 values of BxPc-3 cells after the dendrimer 
solution (concentrations mg/ml) was added and measured the first (black line)  
and third (red line) day. Cell viability was analysed by MTT-assay. 
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Figure 9. Cell viability (%) and IC50 values of BxPc-3 cells after the complex 
solution (concentrations mg/ml) was added and measured the first (black line)  
and third (red line) day. Cell viability was analysed by MTT-assay. 
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Figure 10. Cell viability (%) and IC50 values of HPAC cells after the dendrimer 
solution (concentrations mg/ml) was added and measured the first (black line)  
and third (red line) day. Cell viability was analysed by MTT-assay. 
 
  
13 
 
1E-10 1E-9 1E-8 1E-7 1E-6 1E-5 1E-4 1E-3 0.01 0.1 1 10
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140 HPAC COMPLEX
C
e
ll 
v
ia
b
ili
ty
 %
Concentration mg/ml
 1 DAY POST-INCUBATION IC50=0.03317
 3 DAY POST-INCUBATION  IC50= >0.25
 
Figure 11. Cell viability (%) and IC50 values of HPAC cells after the complex 
solution (concentrations mg/ml) was added and measured the first (black line)  
and third (red line) day. Cell viability was analysed by MTT-assay. (Some 
values of 3 day post-incubation could not be measured by MTT-assay and  
are missing from the figure) 
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Figure 12. Cell viability (%) and IC50 values of PANC1 cells after the dendrimer 
solution (concentrations mg/ml) was added and measured the first (black line)  
and third (red line) day. Cell viability was analysed by MTT-assay. 
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Figure 13. Cell viability (%) and IC50 values of PANC1 cells after the complex 
solution (concentrations mg/ml) was added and measured the first (black line)  
and third (red line) day. Cell viability was analysed by MTT-assay. (Some of  
the values of 3 day post-incubation were out in MTT-assay) 
 
 
Table 3. IC50-values (the half maximal inhibitory concentration) of the pancreatic cancer cell lines exposed 
to DAB16 N/P30 dendrimer solution or N/P30 + pDNA complex solution. The results show recovering of 
the cell survival in 3 days post-incubation compared to 1 day post-incubation values. 
Cell line  Complex  
1 day post-
incubation 
Complex 
3 days post-
incubation 
Dendrimer 1 
day post-
incubation 
 
Dendrimer 3 
days post-
incubation 
PANC1  0.0293 0.28606 0.02058 0.0182 
Mia PaCa  0.00829 0.21835 0.00261 0.10701 
HPAC  0.03137 >0.25 0.03317 0.67707 
BxPc-3  0.00741 0.0259 0.13806 0.08688 
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5.5. Western blot for Itch and p73 
 
The molecular weight marker left some bands out so analyzing the weight was not optimal. α- actin 
(42 kDa) (Figure 14) was near 30-40 kDa. p73 (70-80 kDa) (Figure 15) didn’t give any results and 
Itch (113 kDa) (Figure 16) showed good bands, though unspesific ones. 
 
 
Figure 14.  Westen blot results of a control protein α-actin  
42 kDa. Proteins from cells Mia PaCa-2 (next to the ladder), PANC1 and HPAC. 
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Figure 15. Western blot for p73 (70-80 kDa). 
Only the ladder was seen in the results. 
 
 
Figure 16. Western blot result for Itch protein (113 kDa). Proteins (in order from left to right next 
to the ladder) Mia PaCa-2, PANC1, HPAC, BxPc-3 HeLa and H1299. Only unspecific bands were 
seen. The picture on the right side is a WB of Itch taken from the antibody’s provider (BD  
Transduction Laboratories). Row in the middle is the Itch-antibody dilution 1:1000, which was  
also used in the work. 
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6 DISCUSSION 
 
The main focus of the work was to optimize the conditions for the transfection (complex amount, 
buffers, mediums) and to test the transfection and cytotoxicity of DAB16 nanoparticles in 
pancreatic cancer cells. Transfection succeeded well in optimized conditions, except in BxPc-3 
cells. The reason for the difference in BxPc-3 transfection was not studied, but the reason may be an  
interference in nanoparticle’s pathway into the BxPc-3 cell’s nucleus. Nanoparticles had a cytotoxic 
effect on the cells after transfection but the cells were recovered after 3 days.  
 
Western blotting did not give optimal results and proposals for improvements according to the 
conditions were considered. The use of more gradient gels e.g NuPAGE Bis-Tris gels instead of 
Tris-Glycine gels should be tested. The suitable protein amounts should be studied more and 
compared with the amounts used in other studies. Blocking the membrane could be tried with non-
fat dry milk 5 % instead of BSA (referring to other similar studies) and the blocking time should be 
increased (>1h). Overall, the work gave a good start for studies based on DAB16 N/P30 
nanoparticle-mediated gene transfer in pancreatic cancer cells. Optimizing more Western blotting 
for Itch and p73 to reveal the protein levels is crucial for continuation of the project, where the aim 
is to regulate p73 levels by knocking down Itch ligase. 
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APPENDIXES 
 
APPENDIX 1 Cell culture mediums 
A431 DMEM + 10 % FBS 
B16F10 DMEM + 4 mM L-glutamine adjusted to contain 1.5 g/l sodium bicarbonate and 4.5 g/l 
glucose, fetal bovine serum 10%  
BxPc-3 ATCC-formulated RPMI-1640 medium + add FBS to a final concentration of 10 % 
Mia PaCa-2 ATCC-formulated DMEM + FBS to a final concentration of 10 % + horse serum to a 
final concentration of 2,5 % 
PANC1 ATCC-formulated DMEM + FBS to a final concentration of 10 % 
HPAC ATCC complete growth medium A 1:1 mixture of Dulbecco's modified Eagle's medium 
and Ham's F12 medium containing 1,2 g/L sodium bicarbonate, 2.5 mM L-glutamine, 15 mM 
HEPES and 0.5 mM sodium pyruvate supplemented with 0.002 mg/ml insulin, 0.005 mg/ml 
transferrin, 40 ng/ml hydrocortisone, 10 ng/ml epidermal growth factor and 5% fetal bovine serum 
 
APPENDIX 2 PROTOCOL FOR THE PREPARATION OF THE COMPLEX  
DAB16 with pDNA 
1. pDNA solution (in dextrose 5%) 
100µg/ml pDNA  0,5mg/ml 
 
2. DAB16 solution (in 5% dextrose, mass ratio 5:1 (N/P30) 
100µg/ml pDNA or siRNA  0.66mg/ml 
 
3. DAB16 (in 5% dextrose for mass ratio 1.33:1 (N/P8) 
100µg/ml of pDNA or siRNA  0.177 mg/ml 
 
Add 40µl of pDNA or siRNA solution in each well. Complete with 10µl of HEPES 250mM pH 7.4 
or MES 250mM pH 5.5. Add 150µl of the dendrimer solution over each well. Mix with pipette ~ 
15min. Wait 20min to the utilization of the complexes. 
 
  
 
 
APPENDIX 3 PROTOCOL FOR TRANSFECTION, β-GALACTOSIDASE ANALYSIS AND 
MTT-ASSAY  
Transfection 
 The addition of complexes plus the cell line’s medium (200 µl of complex + 100 µl of medium per 
well). Incubation time 4 hours in 37 degrees (CO2 5 %).  
Betagalactoside analysis 
Solutions: 
2% Triton X-100 in PBS 
2 mg/ml ONPG   
50mM β-mercaptoethanol 
Add to cells and 1h incubation in RT. After incubation measure the absorbance. 
MTT 
Remove the medium from the wells and wash with DPBS. Combine 1ml of Thiazol blue and 10 ml 
of plain DMEM (per 1 96-well plate). Add to wells 100 µl/well. Incubate for 4 hours in 37 degrees. 
Remove the solution and add 100 µl/well of DMSO and incubate for 10 min in 37 degrees. Measure 
the absorbance. 
 
APPENDIX 4 PROTOCOL FOR PROTEIN EXTRACTION (M-PER Mammalian protein 
extraction reagent or RIPA buffer) 
Procedure for Lysis of Suspension-Cultured Mammalian cells 
Centrifuge cell suspension at 2500 for 10min. Discard supernatant. 
(good amount of pancreatic cancer cells is 2 million  results over 10.000 ug/ml of protein ). Add 
50ul of M-PER Reagent to the cell pellet or RIPA buffer. Work with ice when using RIPA buffer. 
Pipette the mixture up and down to resuspend pellet. 1ml of RIPA buffer needs 10ul of antioxidant. 
Shake mixture gently for 10 minutes. Remove the cell debris by centrifugating at 14 000 for 15min. 
Transfer the supernatant to a new tube for analysis (MICRO BCA) 
Measurement of protein concentrations by Micro BCA (www.piercenet.com) 
 
Diluted Albumin for Standard Curve 
Stock (2mg/ml)   
1. Preparation of Diluted Albumin (BSA) Standards: 
  
 
 
 
VIAL VOLUME OF DILUENT 
(ULTRAPURE WATER) 
VOLUME & SOURCE 
OF BSA 
FINAL BSA 
CONCENTRATION 
A 4,5ML 0,5ML OF STOCK 200 UG/ML 
B 8,0ML 2,0ML OF VIAL A 40 UG/ML 
C 4,0ML 4,0ML OF VIAL B 20 UG/ML 
D 4,0ML 4,0ML OF VIAL C 10 UG/ML 
E 4,0ML 4,0ML OF VIAL D 5 UG/ML 
F 4,0ML 4,0ML OF VIAL E 2,5 UG/ML 
G 4,8ML 3,2ML OF VIAL F 1 UG/ML 
H 4,0ML 4,0 ML OF VIAL G 0,5 UG/ML 
I 8,0ML 0 0 UG/ML = BLANK 
 
Make aliquots of A-I and store in -20 degrees. 
 
2. Preparation of the Micro BCA Working Reagent according to instructions 
(For example for 96 wells  prepare WR for 120 wells. Multiply the amount of wells with 150 µl / 
well) 
 
MA 50% 
MB 48% 
MC 2% 
Notice. WR is stable for several days when stored in a closed container at RT. 
 
3. Microplate Procedure 
Pipette 150 µl of each Standard or unknown sample into a microplate well. (Standard Curve is good 
to add as a duplicate). Add 150 µl of the WR to each well and mix plate thoroughly on a plate 
shaker for 30 seconds. Cover plate and incubate at 37 degress for 2 hours. Cool plate at RT. 
Measure the absorbance at or near 562 nm on a plate reader  
  
 
 
 
RIPA buffer  
 
150mM sodium chloride  
1.0 % NP-40 or Triton X-100  
0.5 % sodium deoxycholate  
0.1 % SDS (sodium dodecyl sulphate)  
50 mM Tris, pH 8.0 
 
Protease inhibitor cocktail (SIGMA P2714) 
 
Dissolve the contents of one vial in 100ml of water and use at 1:100 dilution. Can dissolve the 
product in 10ml of water to make 10X stock solution and then dilute 1:10 for use. Aliquots can be 
stored at -20 degrees for 1 month. Use 10 µl / 1ml of RIPA and add to RIPA buffer just before 
using. 
 
APPENDIX 5 PROTOCOL FOR WESTERN BLOTTING 
 
Buffers 
1. Loading buffer 
Can be  made 4X and 6X strength to minimize dilution of the samples. 2X is to be mixed in a 1:1 
ratio with the sample. 
6X (10 ml): 
4 % SDS   x3 = 12 % (0.12 x 10g = 1,2g ) 
10 % 2-mercaptoethanol  x3 = 30 % (0.3 x 10 g = 3,0g) 
20 % Glycerol  x3 = 60% (0.6 x 10ml = 6ml) 
0,004 % Bromophenol blue  x3 = 0.012 % (0.00012 x 10g = 1,2g) 
0,125 M Tris HCL ( x3 = 0.375 M) (M = 121,14 g/mol, m= nM, m= 0,375 mol x 121,14 g/mol = 
45,4 g , (45,4 g / 1000ml) x 10ml  = 0,454 g) 
  
 
 
 
Distilled water add 10ml (already volume is over 6ml) 
Adjust pH to 6.8 with HCL. Use as 1,6µl of loading buffer + 8,4 µl of sample/water.  
 
2. Running buffer 
 
1X Tris-glycine (1 liter): 
 
25 mM Tris Base (0,025 mol x 121,14 g/mol = 3,03 g) 
190 mM Glycine (0,190 mol x 75,07 g/mol = 14,26 g ) 
0,1 % SDS (0,001 x 1000ml = 1g) 
pH should be around 8.3 
 
3. Transfer buffer (2 liters) 
10X: 
144,0 g Glycine  
30 g Tris Base  
7,5 g SDS 
Ultrapure water 1liter 
 
Diluting to 1X: 
100ml of 10X Transfer buffer 
Add 200ml of methanol 
Add 700ml of ultrapure water 
 
4. Rinse buffer (1 liter) 
10 mM Tris-HCl  pH 7.4 (M= 121,1 g/mol, m= nM  0,01M x 121,1 g/mol) 1,211g / 1000ml  
  
 
 
0,15 M NaCl (M= 58,44g/mol, m = nM  0,15M x 58,44 g/mol) 8,766g 
0,01 % NaN3 (not necessary) 
0,05 % NP40 (0,0005 x 1000ml) 500ul  
 
5. Buffer for washing and dilution of antibodies (1 liter)  
(can be used instead of rinse buffer) 
10X PBS 100ml 
1ml Tween 20* 
900 ml ultrapure water 
  
* Taken from WB-protocol of Abcam. Some use 0.05% Tween 20. 
 
6. Blocking buffer 
Rinse buffer or PBST 
5 % of BSA 
  
WESTERN BLOTTING 
 
Electrophoresis 
Laemmli Loading buffer 4X (used 5ul) or 6X (1,6ul) + protein sample + ultrapure water ad 10ul. 
Run time ~ 1,5h 150V. Molecular weight marker MagicMark (Invitrogen). 
 
Staining of the gel 
After electophoresis, place gel in 150ml ultrapure water in loosely covered micowaveble container, 
microwave on high (950-1100 watts) for 1 min until solution almost boils. Shake the gel on an 
orbital shaker for 1 min. Discard the water. Repeat Steps 1-2 two more times. Add 40 ml 
SimplyBlue SafeStain (Invitrogen), microwave on High for 45-60 sec. until the solution almost 
boils. Shake the gel on an orbital shaker for 5min. Discard the stain. Wash the gel in 150ml 
  
 
 
ultrapure water for 10min on a shaker. Add 30ml 20% NaCl to the water and incubate at least 5min. 
The gel can be stored for several weeks in salt solution. 
 
Transfer and blotting 
According to provider’s instructions (Protein transfer- Invitrogen Xcell Mini-Cell) 
 
Chemiluminescence 
According to provider’s instructions (SuperSignal West Pico Chemiluminescent Substrate, Thermo 
Scientific) 
 
APPENDIX 6 DATA -FILES  
Excel 
Origin 
Gel image
  
 
 
 
 
